Antibodies that bind to NKG2D
Novel antibodies targeting NKG2D with high affinity and agonist activity improve immune cell activation, addressing the limitations of current cancer immunotherapies by enhancing treatment efficacy and safety in cancer therapy.
Patent Information
- Application Number
- JP2022502089
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-15
- Filing Date
- 2020-07-14
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-07-14
AI Technical Summary
Current cancer immunotherapies using immune checkpoint inhibitors have low response rates, highlighting the need for novel antibodies that can effectively activate immune cells, such as T cells and NK cells, to enhance cancer treatment.
Development of novel antibodies, including multispecific antibodies, that bind to NKG2D with high affinity and agonist activity, providing improved activation and costimulation of immune cells, while minimizing toxicity and systemic side effects.
These antibodies enhance immune cell activation, particularly of NK cells and CD8 T cells, offering a more effective and safer approach for cancer immunotherapy by circumventing the need for Fc receptor binding, thus reducing systemic side effects.
Smart Images

Figure 0007586889000040 
Figure 0007586889000041 
Figure 0007586889000042
Abstract
Description
[Technical Field]
[0001] The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen-binding molecules, for example, for the activation of T cells and / or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, as well as vectors and host cells containing such polynucleotides. The present invention further relates to methods for producing the antibodies and methods of using the antibodies to treat disease. [Background technology]
[0002] Cancer immunotherapy is a highly active area of research and is currently being used to treat many different types of cancer. Despite promising clinical results obtained with immune checkpoint inhibitors, the percentage of patients who respond to these novel therapies remains low. This clearly demonstrates the high need for novel and differentiated therapeutic approaches that activate the immune system beyond checkpoint inhibition to improve clinical benefit for a larger number of patients with advanced cancer.
[0003] NKG2D is an activating receptor expressed on cytotoxic effector cells that was first described in 1991 (Houchnins et al. (1991) J Exp Med 173, 1017-1020). NKG2D does not have its own signaling motif in its cytoplasmic tail, but associates with the 10 kDa adaptor protein DNAX-activation protein (DAP10) via charged amino acids. DAP10 contains a cytoplasmic YxxM motif that recruits phosphatidylinositol 3-kinase (PI3K) after phosphorylation at its tyrosine residues, ultimately resulting in NK cell activation, cytotoxicity, and costimulation of CD8 T cells. NKG2D is constitutively expressed on almost all NK cells, CD8 T cells, γδ T cells, and a subset of NKT cells, but is not expressed in normal tissues (Bauer et al. (1999) Science 285, 727-729). NKG2D expression can be regulated by various cytokines; IL-2 and IL-15 induce upregulation, whereas TGFβ and IL-21 have been shown to downmodulate NKG2D. NKG2D can also be detected on tumor-infiltrating lymphocytes.
[0004] NKG2D acts as a sensor for transformed cells through the upregulation of NKG2D ligands (NKG2DLs). Many viruses and tumors have evolved mechanisms to evade NKG2D-mediated detection, suggesting that this receptor plays an important role in immune surveillance of tumors and viral infections and represents a potent target for cancer immunotherapy.
[0005] KYK-2.0, an anti-NKG2D antibody with dual antagonistic and agonistic activity, has been reported by Kwong et al. (Kwong et al. (2008) J Mol Biol 384, 1143-1156; WO 2010 / 017103). Bispecific antibodies derived therefrom have been reported in WO 2016 / 134371. Trispecific antibodies targeting NKG2D, CD16, and tumor-associated antigens have been reported, for example, in WO 2018 / 148445.
[0006] However, there remains a need for antibodies that target NKG2D with improved efficacy and / or safety, for example antibodies for use in cancer immunotherapy. Summary of the Invention
[0007] The present invention provides novel antibodies, including multispecific antibodies, that bind to NKG2D and have particularly favorable properties for therapeutic purposes.
[0008] The present inventors have developed novel antibodies that bind to NKG2D and have unexpectedly improved properties. For example, the antibodies bind to both human and cynomolgus monkey NKG2D with high affinity and specifically exhibit binding and agonistic activity (i.e., activation or costimulation) against NKG2D-expressing immune cells. The present invention also encompasses multispecific antigen-binding molecules that incorporate the novel NKG2D antibodies and bind to NKG2D and a second antigen, combining good efficacy and productivity with low toxicity and favorable pharmacokinetic properties. These (multispecific) antibodies can be used for therapeutic purposes, particularly in the treatment of cancer, particularly cancer immunotherapy. Importantly, the (multispecific) antibodies of the present invention are particularly suitable for combination with other immunotherapeutic agents, such as T cell activators.
[0009] In a first aspect, the present invention provides an antibody that binds to NKG2D, comprising: (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 selected from the group consisting of SEQ ID NO: 74, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, and SEQ ID NO: 105, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78; (ii) a VH comprising an HCDR1 of SEQ ID NO: 65, an HCDR2 of SEQ ID NO: 66, and an HCDR3 of SEQ ID NO: 67, and a VL comprising an LCDR1 of SEQ ID NO: 68, an LCDR2 of SEQ ID NO: 69, and an LCDR3 of SEQ ID NO: 70; (iii) a VH comprising an HCDR1 of SEQ ID NO: 1, an HCDR2 of SEQ ID NO: 2, and an HCDR3 of SEQ ID NO: 3, and a VL comprising an LCDR1 of SEQ ID NO: 4, an LCDR2 of SEQ ID NO: 5, and an LCDR3 of SEQ ID NO: 6; (iv) a VH comprising an HCDR1 of SEQ ID NO: 25, an HCDR2 of SEQ ID NO: 26, and an HCDR3 of SEQ ID NO: 27, and a VL comprising an LCDR1 of SEQ ID NO: 28, an LCDR2 of SEQ ID NO: 29, and an LCDR3 of SEQ ID NO: 30; (v) a VH comprising an HCDR1 of SEQ ID NO: 49, an HCDR2 of SEQ ID NO: 50, and an HCDR3 of SEQ ID NO: 51, and a VL comprising an LCDR1 of SEQ ID NO: 52, an LCDR2 of SEQ ID NO: 53, and an LCDR3 of SEQ ID NO: 54; (vi) a VH comprising an HCDR1 of SEQ ID NO: 57, an HCDR2 of SEQ ID NO: 58, and an HCDR3 of SEQ ID NO: 59, and a VL comprising an LCDR1 of SEQ ID NO: 60, an LCDR2 of SEQ ID NO: 61, and an LCDR3 of SEQ ID NO: 62; (vii) a VH comprising an HCDR1 of SEQ ID NO: 9, an HCDR2 of SEQ ID NO: 10, and an HCDR3 of SEQ ID NO: 11, and a VL comprising an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 13, and an LCDR3 of SEQ ID NO: 14; (viii) VH comprising an HCDR1 of SEQ ID NO: 17, an HCDR2 of SEQ ID NO: 18, and an HCDR3 of SEQ ID NO: 19, and VL comprising an LCDR1 of SEQ ID NO: 20, an LCDR2 of SEQ ID NO: 21, and an LCDR3 of SEQ ID NO: 22; (ix) a VH comprising an HCDR1 of SEQ ID NO: 33, an HCDR2 of SEQ ID NO: 34, and an HCDR3 of SEQ ID NO: 35, and a VL comprising an LCDR1 of SEQ ID NO: 36, an LCDR2 of SEQ ID NO: 37, and an LCDR3 of SEQ ID NO: 38; or (x) An antibody is provided, comprising a first antigen-binding domain comprising a VH comprising an HCDR1 of SEQ ID NO: 41, an HCDR2 of SEQ ID NO: 42, and an HCDR3 of SEQ ID NO: 43, and a VL comprising an LCDR1 of SEQ ID NO: 44, an LCDR2 of SEQ ID NO: 45, and an LCDR3 of SEQ ID NO: 46.
[0010] In one aspect, the present invention provides an antibody that binds to NKG2D, comprising: (i) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, and / or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:80; (ii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 71, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 72; (iii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 7, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 8; (iv) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 31, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 32; (v) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 55, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 56; (vi) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 63, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 64; (vii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 15, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 16; (viii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 23, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 24; (ix) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 39, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 40; or (x) an antibody comprising a first antigen-binding domain comprising a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 47, and / or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 48.
[0011] In one aspect, the antibody is an IgG, particularly an IgG1 antibody. In one embodiment, the antibody is a full-length antibody. In another aspect, the antibody is an antibody fragment selected from the group consisting of an Fv molecule, an scFv molecule, an Fab molecule, and an F(ab')2 molecule.
[0012] In one embodiment, the antibody is a multispecific, particularly a bispecific, antibody. In one embodiment, the antibody comprises a second antigen-binding domain that binds to a second antigen. In one embodiment, the second antigen is a target cell antigen, particularly a tumor cell antigen.
[0013] In one aspect, the antibody comprises an Fc domain composed of a first subunit and a second subunit. In one aspect, the Fc domain is an IgG, particularly an IgG1, Fc domain. In one aspect, the Fc domain is a human Fc domain. In one aspect, the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor and / or reduce effector function. In one aspect, the antibody does not bind to FcγRIIIa (CD16a).
[0014] In one embodiment, the first and / or second antigen binding domain is a Fab molecule.
[0015] In some embodiments, the first antigen-binding domain is a Fab molecule in which the variable domains VL and VH or the constant domains CL and CH1 of the Fab light and heavy chains, particularly the variable domains VL and VH, are replaced by one another. In one such embodiment, the second antigen-binding domain is a conventional Fab molecule. In a further such embodiment, the second antigen-binding domain is a Fab molecule wherein in the constant domain CL the amino acid at position 124 is independently substituted by lysine (K), arginine (R), or histidine (H) (Kabat numbering), and the amino acid at position 123 is independently substituted by lysine (K), arginine (R), or histidine (H) (Kabat numbering), and wherein in the constant domain CHI the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0016] In an alternative embodiment, the second antigen-binding domain is a Fab molecule in which the variable domains VL and VH or the constant domains CL and CH1 of the Fab light and heavy chains, in particular the variable domains VL and VH, are replaced by one another. In one such embodiment, the first antigen-binding domain is a conventional Fab molecule. In a further such embodiment, the first antigen-binding domain is a Fab molecule wherein in the constant domain CL the amino acid at position 124 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), and the amino acid at position 123 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), and wherein in the constant domain CHI the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0017] In one embodiment, the first antigen-binding domain and the second antigen-binding domain are each a Fab molecule, and the antibody comprises an Fc domain composed of a first subunit and a second subunit, and either (i) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain, or (ii) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.
[0018] In one embodiment, the Fc domain comprises a modification that promotes association of a first subunit of the Fc domain with a second subunit: In one embodiment, in the CH3 domain of the first subunit of the Fc domain, amino acid residues are replaced with amino acid residues having a larger side chain mass, thereby creating a protrusion in the CH3 domain of the first subunit that can be positioned in a cavity in the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain, amino acid residues are replaced with amino acid residues having a smaller side chain mass, thereby creating a cavity in the CH3 domain of the second subunit into which the protrusion in the CH3 domain of the first subunit can be positioned.
[0019] According to further aspects of the present invention, there are provided isolated polynucleotides encoding the antibodies of the invention, and host cells comprising the isolated polynucleotides of the invention. In another aspect, there is provided a method for producing an antibody that binds to NKG2D, comprising the steps of (a) culturing a host cell of the invention under conditions suitable for expression of the antibody, and, optionally, (b) recovering the antibody. The present invention also encompasses antibodies that bind to NKG2D produced by the methods of the invention.
[0020] The present invention further provides a pharmaceutical composition comprising an antibody of the present invention and a pharmaceutically acceptable carrier.
[0021] The present invention also encompasses methods of using the antibodies and pharmaceutical compositions of the present invention. In one aspect, the present invention provides an antibody or pharmaceutical composition according to the present invention for use as a medicament. In one aspect, the present invention provides an antibody or pharmaceutical composition according to the present invention for use in treating a disease. In a specific aspect, the disease is cancer. In a particular aspect, the use is in combination with a T cell activator, such as an antibody that binds to CD3, particularly a bispecific antibody that binds to CD3 and a target cell antigen, particularly a tumor cell antigen.
[0022] Also provided is the use of an antibody or pharmaceutical composition according to the invention in the manufacture of a medicament, and the use of an antibody or pharmaceutical composition according to the invention in the manufacture of a medicament for the treatment of a disease, particularly cancer. In a particular embodiment, the treatment is in combination with a T cell activator, such as an antibody that binds to CD3, particularly a bispecific antibody that binds to CD3 and a target cell antigen, particularly a tumor cell antigen. The present invention also provides a method for treating a disease, particularly cancer, in an individual, comprising administering to the individual an effective amount of an antibody or pharmaceutical composition according to the invention. In a particular embodiment, the method further comprises administering a T cell activator, such as an antibody that binds to CD3, particularly a bispecific antibody that binds to CD3 and a target cell antigen, particularly a tumor cell antigen. [Brief explanation of the drawings]
[0023] [Figure 1] Schematic diagram of the NKG2D receptor and MIC-B ligand constructed in Example 1. The NKG2D receptor and MIC-B ligand were cloned as monomers ("mono") or dimers ("di") for the receptor or ligand portion of the construct, with or without fusion to a human or mouse Fc domain. All constructs except di huNKG2D ECD mu IgG1 Fc contain at least one avi tag for site-specific biotinylation. (A) his avi huNKG2D ECD, (B) mono huNKG2D ECD Fc kh avi, (C) di huNKG2D ECD Fc avi, (D) di huNKG2D ECD mu IgG1 Fc, (E) di cyNKG2D ECD Fc avi, (F) di muNKG2D ECD Fc avi, (G) ECD FL MIC-B Fc avi. [Figure 2] Screening of anti-NKG2D antibodies for MIC-B competition by ELISA. Percent inhibition of NKG2D binding to MIC-B is shown relative to binding of recombinant biotinylated human NKG2D to plate-immobilized MIC-B without anti-NKG2D antibody. [Figure 3]Redirected lysis of target cells by anti-NKG2D antibodies. Percent cell killing by anti-NKG2D antibodies as determined by calcein release from labeled P815 target cells. Antibody concentrations for each clone are (from left to right): 40.0, 13.33, 4.44, 1.48, 0.49, 0.165, 0.055, 0.018, 0.006, and 0.002 μg / ml. [Figure 4] Example SPR sensorgram showing two injections of antibodies binding different epitopes. [Figure 5] Binding of anti-NKG2D antibodies to (A) the human NK cell line NK92, (B) expanded human NK cells, (C) expanded human γδ T cells, and (D) human CD8 T cells compared to a freshly isolated, non-binding control antibody as measured by flow cytometry. [Figure 6] Activation of NKG2D-positive immune cells by anti-NKG2D antibody. The human NK cell line NK92 was co-cultured with anti-NKG2D antibody (IgG1) captured on protein A beads. NK cell activation was determined by measuring INFγ release into the supernatant using the CBA technique. [Figure 7] Activation of NKG2D-positive immune cells by anti-NKG2D antibody. The human NK cell line NK92 was co-cultured with anti-NKG2D antibody (IgG1) captured on protein A beads (A) or in solution (B). NK cell activation was determined by measuring INFγ release into the supernatant using the CBA technique. [Figure 8] Activation of NKG2D-positive immune cells by anti-NKG2D antibody. Human primary expanded NK cells were co-cultured with anti-NKG2D antibody (IgG1) captured on protein A beads. NK cell activation was determined by measuring the release of INFγ and TNFα into the supernatant using the CBA technique. [Figure 9] Activation of NKG2D-positive immune cells by anti-NKG2D antibodies. Human primary expanded γδ T cells were co-cultured with anti-NKG2D antibodies (IgG1) captured on protein A beads. NK cell activation was determined by measuring the release of TNFα into the supernatant using the CBA technique. [Figure 10]Costimulation of CD8 T cell clones with anti-NKG2D antibody. NLV-specific (A and B) and MART1-specific (C) CD8 T cell clones were cultured on plates containing coated anti-NKG2D antibody (IgG1) in combination with a fixed concentration of CD3 antibody (A and C) or in the absence of CD3 antibody (B). Upregulation of CD25, as determined by flow cytometry, was used as a marker for activation of CD8 T cell clones. [Figure 11] Alignment of the humanized VH domain of anti-NKG2D antibody 395 compared to the non-humanized parent rabbit sequence 395 (P1AE4972), in which the unpaired cysteine in HCDR2 has been replaced with a serine (position indicated by an asterisk). [Figure 12] Schematic diagram of NKG2D bispecific antibody formats (with CEA as an exemplary second specificity). (A) D format, (B) J format, (C) K format, (D) I format, (E) L format, (F) M format. [Figure 13] Several anti-NKG2D antibodies were tested for functional activity as bispecific constructs targeting CEA in a Jurkat NFAT NKG2D reporter cell assay on MKN-45 cells in combination with 5 nM CEA-TCB. Activation of Jurkat NFAT NKG2D reporter cells was determined by measuring luminescence 5 hours after treatment. [Figure 14] Anti-NKG2D antibody 320 was tested for its functional activity in a different bispecific format (with CEA as the second specificity) in a Jurkat NFAT NKG2D reporter cell assay in MKN-45 cells in combination with 5 nM CEA-TCB. Activation of Jurkat NFAT NKG2D reporter cells was determined by measuring luminescence 5 hours after treatment. [Figure 15]Binding of NKG2DxCEA bispecific antibody and anti-NKG2D antibody 320 to NKG2D-positive NK92 cells (A) and CEA-positive LS180 cells (B) as measured by flow cytometry and compared to the respective IgG. [Figure 16] Anti-NKG2D antibodies 5C5 (A) and 013 (B) were tested for their functional activity in a different bispecific format (with CEA as the second specificity) in a Jurkat NFAT NKG2D reporter cell assay in MKN45 cells in combination with 5 nM CEA-TCB. Activation of Jurkat NFAT NKG2D reporter cells was determined by adding treatment and measuring luminescence 5 hours later. [Figure 17] The functional activity of two bispecific formats (M and I) of anti-NKG2D antibody 395 was compared to the functional activity of the I format of anti-NKG2D antibody 320 in a Jurkat NFAT NKG2D reporter cell assay on MKN45 cells in combination with 5 nM CEA-TCB. Activation of Jurkat NFAT NKG2D reporter cells was determined by adding treatment and measuring luminescence 5 hours later. [Figure 18] Binding of NKG2DxCEA bispecific antibody and anti-NKG2D antibody 395 to NKG2D-positive NK92 cells (A) and CEA-positive LS180 cells (B) as measured by flow cytometry and compared to the respective IgG. [Figure 19] The functional activity of two different NKG2D x CEA bispecific antibodies was tested in a Jurkat NFAT NKG2D reporter cell assay in the presence of tumor cell lines with different CEA expression levels. Activation of Jurkat NFAT NKG2D reporter cells was determined by measuring luminescence 5 hours after treatment. (A) Bispecific antibody with anti-NKG2D antibody 320 in I format. (B) Bispecific antibody with anti-NKG2D antibody 395 in M format. [Figure 20]Binding of bispecific antibodies with M-format anti-NKG2D antibody 395 to CD8 T cells (A), NK cells (B), and CD4 T cells (C) within freshly isolated PBMCs as measured by flow cytometry. [Figure 21] Activation of CD8 T cells by T cell bispecific antibodies (TCBs) in M format and the combination of NKG2DxCEA bispecific antibodies with anti-NKG2D antibody 395, as measured by flow cytometry. (A, B) Upregulation of CD69 (A) and CD25 (B) on CD8 T cells in PBMCs by 48-hour treatment with LS180 tumor cells combined with 0.1 nM CEA-TCB (2) alone or 0.4 nM NKG2DxCEA bispecific antibody. (C, D) Upregulation of CD69 (C) and CD25 (D) on CD8 T cells in PBMCs by 48-hour treatment with MKN-45 cells combined with CEA-TCB alone or 2 nM NKG2DxCEA bispecific antibody. [Figure 22] Binding of humanized variants of the bispecific M-format anti-NKG2D antibody 395 to NKG2D expressed on NK92 cells was measured by flow cytometry and compared to the parent anti-NKG2D antibody (P1AE4972). (A) P1AE4973, P1AE4975, and P1AE4977. (B) P1AE4978, P1AE4979, P1AE4980, and P1AE4981. [Figure 23] The functional activity of humanized variants of the anti-NKG2D antibody 395 in the bispecific M format was tested in Jurkat NFAT NKG2D reporter cell assays on MKN-45 cells (A, B) and HT-29 cells (C, D) in combination with 5 nM CEA-TCB, and the activity of each format was compared to that of the parent antibody (P1AE4972). Activation of Jurkat NFAT NKG2D reporter cells was determined by measuring luminescence 5 hours after treatment. [Figure 24]The functional activity of the bispecific M-format humanized anti-NKG2D antibody variant P1AE4980 in combination with TCB was tested in a Jurkat NFAT NKG2D reporter cell assay using a CEA-negative tumor cell line, HeLa (A), and two CEA-positive tumor cell lines, HT29 (B) and MKN-45 (C). Activation of Jurkat NFAT NKG2D reporter cells was determined by measuring luminescence 5 hours after treatment. [Figure 25] The functional activity of the NKG2DxCEA bispecific antibody (humanized anti-NKG2D antibody variant P1AE4980, M-format) in combination with CEA-TCB was tested in a Jurkat NFAT NKG2D reporter cell assay on MKN-45 cells in the presence of increasing concentrations of shed CEA (sCEA) (A). In parallel, the functional activity of the NKG2DxCEA bispecific antibody in combination with CEA-TCB and CEA-TCB alone was tested as a reference in the same assay (B). Activation of Jurkat NFAT NKG2D reporter cells was determined by measuring luminescence 5 hours after treatment. [Figure 26] The functional activity of the NKG2D x CEA bispecific antibody (humanized anti-NKG2D antibody variant P1AE4980, M-format) with CEA-TCB in the presence of the soluble NKG2D ligands MICA (sMICA, 10 μg / ml) or ULBP2 (sULBP2, 10 μg / ml) was compared to the activity of the NKG2D x CEA bispecific antibody with CEA-TCB (in the absence of ligand) in a Jurkat NFAT NKG2D reporter cell assay on MKN-45 cells. Activation of Jurkat NFAT NKG2D reporter cells was determined by measuring luminescence 5 hours after treatment. [Figure 27] Schematic diagram of the NKG2DxCEA bispecific antibody prepared in Example 19, comprising antibody P1AE4980 as the NKG2D binder and antibody huA5B7 and its affinity matured variants as the CEA binder. [Figure 28]The binding of bispecific NKG2DxCEA antibodies with two affinity-matured variants of the anti-CEA antibody huA5B7, P002.139 and P001.177, to CEA expressed on LS180 tumor cells was compared to the binding of the corresponding bispecific NKG2DxCEA antibody containing the parent CEA binder huA5B7. Bispecific antibody binding was detected using a fluorescently labeled secondary antibody, and fluorescence was analyzed by flow cytometry. [Figure 29] Bispecific NKG2DxCEA antibodies containing huA5B7, P002.139, or P001.177 as the CEA binder were tested for their functional activity in a Jurkat NFAT NKG2D reporter cell assay against highly CEA-expressing MKN45 cells in combination with 5 nM CEA-TCB in 96-well plates. Activation of Jurkat NFAT NKG2D reporter cells was determined by adding treatment and measuring luminescence 5 hours later. [Figure 30] Bispecific NKG2DxCEA antibodies containing huA5B7, P002.139, or P001.177 as the CEA binder were tested for their functional activity in a Jurkat NFAT NKG2D reporter cell assay against medium-expressing LS180 cells (A, B) and low-expressing HT29 cells (C, D) in combination with 5 nM CEA-TCB (A, C) or 1 nM CEA-TCB (B, D) in a 384-well plate. Activation of Jurkat NFAT NKG2D reporter cells was determined by adding treatment and measuring luminescence 3 hours later. [Figure 31] The anti-NKG2D antibodies C26, ADI27743, and P1AE4980 were tested for binding to NKG2D on NK92 cells by flow cytometry. Bound antibody was detected with a fluorescently labeled secondary antibody. [Figure 32] Bispecific NKG2DxCEA antibodies containing C26, ADI27743, or P1AE4980 as the NKG2D binder were tested for binding to NKG2D on NK92 cells by flow cytometry. Bound antibody was detected with a fluorescently labeled secondary antibody. [Figure 33]Bispecific NKG2DxCEA antibodies containing C26, ADI27743, or P1AE4980 as the NKG2D binder were tested in a Jurkat NFAT NKG2D reporter cell assay against the highly CEA-expressing MKN45 tumor cell line in combination with 5 nM CEA-TCB. Activation of Jurkat NFAT NKG2D reporter cells was determined by adding treatment and measuring luminescence 6 hours later. [Figure 34] Bispecific NKG2DxCEA antibodies containing C26, ADI27743, or P1AE4980 as the NKG2D binder were tested in a Jurkat NFAT NKG2D reporter cell assay against the low CEA-expressing HT-29 tumor cell line in combination with 5 nM CEA-TCB. Activation of Jurkat NFAT NKG2D reporter cells was determined by adding treatment and measuring luminescence 6 hours later. [Figure 35] PBMCs were treated with NKG2D antibodies containing wild-type or effector-silent Fc domains for 24 hours, after which CD69 upregulation on NK cells was determined by flow cytometry. DETAILED DESCRIPTION OF THE INVENTION
[0024] I. Definition Terms are used herein as commonly used in the art unless otherwise defined below.
[0025] As used herein, the terms "first," "second," or "third," with respect to antigen-binding domains, etc., are used for convenience of distinction when more than one of each type of moiety is present. The use of these terms is not intended to confer a particular order or orientation of the moieties unless explicitly indicated as such.
[0026] The terms "anti-NKG2D antibody" and "antibody that binds to NKG2D" refer to an antibody that can bind to NKG2D with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting NKG2D. In one embodiment, the degree of binding of an anti-NKG2D antibody to an unrelated, non-NKG2D protein is less than about 10% of the binding of the antibody to NKG2D, as measured, for example, by surface plasmon resonance (SPR). In certain embodiments, an antibody that binds to NKG2D has an equilibrium dissociation constant (K) of ≦1 μM, ≦500 nM, ≦200 nM, or ≦100 nM. D For example, the antibody has a K of 1 μM or less as measured by SPR. D An antibody is said to "specifically bind" to NKG2D if it has the following structure: In certain embodiments, an anti-NKG2D antibody binds to an epitope of NKG2D that is conserved among NKG2D from different species.
[0027] Conversely, an antibody that "does not bind" to a particular antigen is unable to bind to that antigen with sufficient affinity to be useful as a diagnostic and / or therapeutic agent in targeting that antigen. In certain embodiments, an antibody that does not bind to a particular antigen has a dissociation constant (K) for that antigen of greater than 1 μM. D )
[0028] The term "antibody" is used herein in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0029] An "antibody fragment" is a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv and scFab), single-domain antibodies, and multispecific antibodies formed from antibody fragments. For a review of certain antibody fragments, see Hollinger and Hudson, Nature Biotechnology 23:1126-1136 (2005).
[0030] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure.
[0031] The term "monoclonal antibody," as used herein, refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., each individual antibody within the population is identical and / or binds to the same epitope, but does not include possible variant antibodies, including, for example, naturally occurring mutations or mutations that arise during production of a monoclonal antibody preparation, and such variants are generally present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies can be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such as those and other exemplary methods for producing monoclonal antibodies described herein.
[0032] An "isolated" antibody is one that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as determined by electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse-phase HPLC, affinity chromatography, size exclusion chromatography) methods. For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007). In some embodiments, the antibody provided by the present invention is an isolated antibody.
[0033] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, and the remainder of the heavy and / or light chain is derived from a different source or species.
[0034] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues derived from non-human CDRs and human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDRs correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. Such variable domains are referred to herein as "humanized variable regions." A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues were derived), e.g., to restore or improve antibody specificity or affinity. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
[0035] A "human antibody" is an antibody having an amino acid sequence corresponding to an antibody produced by a human or human cell, or an antibody of non-human origin that utilizes human antibody-encoding sequences, such as the human antibody repertoire. This definition of a human antibody specifically excludes humanized antibodies, which contain non-human antigen-binding residues. In certain aspects, a human antibody is derived from a non-human transgenic mammal, such as a mouse, rat, or rabbit. In certain aspects, a human antibody is derived from a hybridoma cell line. Antibodies or antibody fragments isolated from a human antibody library are also considered human antibodies or human antibody fragments of the invention.
[0036] The term "antigen-binding domain" refers to a part of an antibody comprising an area that binds to and is complementary to part or all of an antigen. An antigen-binding domain may be provided, for example, by one or more antibody variable domains (also called antibody variable regions). In a preferred embodiment, the antigen-binding domain comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).
[0037] A "variable region" or "variable domain" is a domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains (VH and VL, respectively) of a native antibody generally have similar structures, and each domain contains four conserved framework regions (FR) and complementarity-determining regions (CDR). See, for example, Kindt et al., Kuby Immunology, 6 thed., W.H. Freeman & Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Moreover, antibodies that bind to a specific antigen may be isolated by using the VH or VL domain of an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991). When used herein in conjunction with variable region sequences, "Kabat numbering" refers to the numbering system described by Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).
[0038] As used herein, the amino acid positions of all heavy and light chain constant regions and domains are numbered according to the Kabat numbering system as described in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), and is referred to herein as "Kabat numbering" or "Kabat numbering." Specifically, the Kabat numbering system (see Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), pp. 647-660) is used for the light chain constant domains CL of kappa and lambda isotypes, and the Kabat EU index numbering system (see pp. 661-723) is used for the heavy chain constant domains (CH1, hinge, CH2, and CH3), which is further clarified by reference to "Kabat EU index numbering" or "Kabat EU index numbering."
[0039] As used herein, the term "hypervariable region" or "HVR" refers to each of the regions of an antibody variable domain, e.g., "complementarity determining regions" (CDRs), that are hypervariable in sequence and determine antigen binding specificity. Generally, antibodies contain six CDRs, three in the VH (HCDR1, HCDR2, HCDR3) and three in the VL (LCDR1, LCDR2, LCDR3). Exemplary CDRs herein include: (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs located at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and (c) Antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262:732-745 (1996)).
[0040] Unless otherwise specified, CDRs are determined according to Kabat et al., supra. Those skilled in the art will understand that CDR designations can be determined according to Chothia, supra, McCallum, supra, or any other scientifically accepted nomenclature system.
[0041] "Framework" or "FR" refers to variable domain residues other than the complementarity-determining regions (CDRs). The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, the HVR and FR sequences generally appear in the following order in VH (or VL): FR1-HCDR1 (LCDR1)-FR2-HCDR2 (LCDR2)-FR3-HCDR3 (LCDR3)-FR4.
[0042] Unless otherwise indicated, CDR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.
[0043] For purposes herein, an "acceptor human framework" is a framework that comprises the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence, or may comprise amino acid sequence changes. In some aspects, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some aspects, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or the human consensus framework sequence.
[0044] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as found in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda, MD (1991), vols. 1-3.
[0045] The term "immunoglobulin molecule" refers to a protein having the structure of a naturally occurring antibody. For example, immunoglobulins of the IgG class are heterotetrameric glycoproteins of approximately 150,000 daltons, composed of two light chains and two heavy chains disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH), also called a variable heavy domain or heavy chain variable region, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL), also called a variable light domain or light chain variable region, followed by a constant light domain (CL), also called a light chain constant region. Immunoglobulin heavy chains may be assigned to one of five types, called α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which may be further divided into subtypes, e.g., γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1), and α2 (IgA2). Immunoglobulin light chains may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domain. Immunoglobulins essentially consist of two Fab molecules and an Fc domain connected via an immunoglobulin hinge region.
[0046] The "class" of an antibody or immunoglobulin refers to the type of constant domain or constant region possessed by the antibody or immunoglobulin heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, some of which may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0047] A "Fab molecule" refers to a protein consisting of the VH and CH1 domains of an immunoglobulin heavy chain (a "Fab heavy chain") and the VL and CL domains of an immunoglobulin light chain (a "Fab light chain").
[0048] A "crossover" Fab molecule (also referred to as "Crossfab") refers to a Fab molecule in which the variable and constant domains of the Fab heavy and light chains have been exchanged (i.e., replaced with each other), i.e., the crossover Fab molecule comprises a peptide chain consisting of a light chain variable domain VL and a heavy chain constant domain 1 CH1 (VL-CH1, from N- to C-terminal), and a peptide chain consisting of a heavy chain variable domain VH and a light chain constant domain CL (VH-CL, from N- to C-terminal). For clarity, in a crossover Fab molecule in which the variable domains of the Fab light chain and the Fab heavy chain have been exchanged, the peptide chain comprising the heavy chain constant domain 1 CH1 is referred to herein as the "heavy chain" of the (crossover) Fab molecule. Conversely, in a crossover Fab molecule in which the constant domains of the Fab light chain and the Fab heavy chain have been exchanged, the peptide chain comprising the heavy chain variable domain VH is referred to herein as the "heavy chain" of the (crossover) Fab molecule.
[0049] In contrast, a "conventional" Fab molecule refers to a Fab molecule in its native format, i.e., comprising a heavy chain (VH-CH1, N- to C-terminally) composed of a heavy chain variable domain and a constant domain, and a light chain (VL-CL, N- to C-terminally) composed of a light chain variable domain and a constant domain.
[0050] The term "Fc domain" or "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain containing at least a portion of the constant region. The term includes native-sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl terminus of the heavy chain. However, antibodies produced by host cells may undergo post-translational cleavage of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Thus, upon expression of a particular nucleic acid molecule encoding a full-length heavy chain, antibodies produced by host cells may comprise the full-length heavy chain or a cleaved variant of the full-length heavy chain. This may be the case where the final two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, according to the Kabat EU index). Thus, the C-terminal lysine (Lys447) of the Fc region, or the C-terminal glycine (Gly446) and lysine (Lys447) may or may not be present. The amino acid sequence of a heavy chain comprising an Fc region (or a subunit of an Fc domain as defined herein) is shown herein without the C-terminal glycine-lysine dipeptide, unless otherwise indicated. In one aspect, a heavy chain comprising an Fc region (subunit) as specified herein, comprised in an antibody according to the invention, comprises an additional C-terminal glycine-lysine dipeptide (G446 and K447, numbering according to the Kabat EU index). In one aspect, a heavy chain comprising an Fc region (subunit) as specified herein, comprised in an antibody according to the invention, comprises an additional C-terminal glycine residue (G446, numbering according to the Kabat EU index). Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system (also referred to as the EU index) as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also supra).A "subunit" of an Fc domain, as used herein, refers to one of the two polypeptides that form a dimeric Fc domain, i.e., a polypeptide comprising the C-terminal constant region of an immunoglobulin heavy chain, capable of stable self-association. For example, a subunit of an IgG Fc domain comprises the IgG CH2 and IgG CH3 constant domains.
[0051] By "fused" is meant that the components (e.g., a Fab molecule and an Fc domain subunit) are joined either directly by a peptide bond or via one or more peptide linkers.
[0052] The term "multispecific" means that an antibody can specifically bind to at least two distinct antigenic determinants. A multispecific antibody can be, for example, a bispecific antibody. Typically, a bispecific antibody contains two antigen-binding sites, each specific for a different antigenic determinant. In certain embodiments, a multispecific (e.g., bispecific) antibody can simultaneously bind to two antigenic determinants, particularly two antigenic determinants expressed on two separate cells.
[0053] The term "valency," as used herein, refers to the presence of a specific number of antigen-binding sites within an antigen-binding molecule. In this context, the term "monovalent binding to an antigen" refers to the presence of one (and not more than one) antigen-binding site specific for an antigen within the antigen-binding molecule.
[0054] "Antigen-binding site" refers to the site of an antigen-binding molecule, i.e., one or more amino acid residues, that interacts with an antigen. For example, the antigen-binding site of an antibody comprises amino acid residues from the complementarity-determining regions (CDRs). A native immunoglobulin molecule typically contains two antigen-binding sites, and a Fab molecule typically has one antigen-binding site.
[0055] As used herein, the term "antigenic determinant" or "antigen" refers to the site on a polypeptide macromolecule to which an antigen-binding domain binds (e.g., a contiguous stretch of amino acids or a conformational configuration composed of different regions of non-contiguous amino acids), forming an antigen-binding domain-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virally infected cells, on the surface of other diseased cells, on the surface of immune cells, free in serum, and / or in the extracellular matrix (ECM). In a preferred embodiment, the antigen is a human protein.
[0056] Unless otherwise specified, "NKG2D" refers to any native NKG2D from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term encompasses "full-length," unprocessed NKG2D and any form of NKG2D resulting from intracellular processing. The term also encompasses naturally occurring variants of NKG2D, such as splice variants or allelic variants. In one aspect, the NKG2D is human NKG2D, particularly the extracellular domain (ECD) of human NKG2D. The amino acid sequence of human NKG2D and its ECD are set forth in SEQ ID NO: 87 and SEQ ID NO: 88, respectively. See also UniProt (www.uniprot.org) entry P26718 (version 176). In another embodiment, the NKG2D is cynomolgus monkey (Macaca fascicularis) NKG2D, particularly the ECD of cynomolgus monkey NKG2D. The amino acid sequences of cynomolgus monkey NKG2D and its ECD are set forth in SEQ ID NO: 89 and SEQ ID NO: 90, respectively. See also UniProt entry P61252 (version 71). In another embodiment, the NKG2D is mouse (Mus musculus) NKG2D, particularly the ECD of mouse NKG2D. The amino acid sequences of mouse NKG2D and its ECD are set forth in SEQ ID NO: 91 and SEQ ID NO: 92, respectively. See also UniProt entry O54709 (version 151). In certain embodiments, the antibodies of the present invention bind to an epitope of NKG2D that is conserved among NKG2D antigens from different species, particularly human and cynomolgus monkey NKG2D. In a preferred embodiment, the antibody binds to human NKG2D. In one aspect, the first antigen-binding domain is cross-reactive with (i.e., binds to) human and cynomolgus NKG2D.
[0057] "Target cell antigen," as used herein, refers to an antigenic determinant displayed on the surface of a target cell, e.g., a cell within a tumor, such as a cancer cell or (in the case of a "tumor cell antigen") a tumor stromal cell. Preferably, the target cell antigen is not NKG2D and / or is expressed on a different cell than NKG2D. In one embodiment, the target cell antigen is CEA.
[0058] "CEA" refers to carcinoembryonic antigen (also known as carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)). The amino acid sequence of human CEA is shown in UniProt entry P06731 (version 188). As used herein, unless otherwise specified, "CEA" refers to any native CEA from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term encompasses "full-length," unprocessed CEA and any form of CEA resulting from intracellular processing. The term also encompasses naturally occurring variants of CEA, such as splice variants or allelic variants. In one embodiment, the CEA is human CEA. In one embodiment, the CEA is cell membrane-bound CEA. In one embodiment, the CEA is CEA expressed on the surface of a cell, e.g., a cancer cell.
[0059] "Affinity" refers to the strength of the total non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the specific binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y is generally determined by the dissociation constant (K D ) Affinity can be measured by well-established methods known in the art, including those described herein. A preferred method for measuring affinity is surface plasmon resonance (SPR).
[0060] An "affinity matured" antibody refers to an antibody that contains one or more alterations in one or more complementarity determining regions (CDRs), compared to a parent antibody that does not possess those alterations, which alterations improve the affinity of the antibody for antigen.
[0061] "Reduced binding," e.g., reduced binding to an Fc receptor, refers to a decrease in affinity for the respective interaction, e.g., as measured by SPR. For clarity, the term also includes a reduction in affinity to zero (or below the detection limit of the analytical method), i.e., a complete cessation of the interaction. Conversely, "increased binding" refers to an increase in binding affinity for a particular interaction.
[0062] As used herein, "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. Suitable assays for measuring T cell activation are known in the art and described herein.
[0063] As used herein, "T cell activator" refers to a molecule that can induce T cell activation by binding to and activating (a component of) a T cell receptor, e.g., CD3. Thus, an exemplary T cell activator can be an antibody that binds to CD3, particularly the epsilon subunit of CD3. Particular T cell activators useful in the present invention are bispecific antibodies that bind to CD3 and a target cell antigen, such as a tumor cell antigen. Such T cell activating bispecific antibodies are also referred to herein as "T cell bispecific antibodies" or "TCBs."
[0064] Unless otherwise specified, "CD3" refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term encompasses "full-length," unprocessed CD3 and any form of CD3 resulting from intracellular processing. The term also encompasses naturally occurring variants of CD3, such as splice variants or allelic variants. In one aspect, the CD3 is human CD3, particularly the epsilon subunit of human CD3 (CD3ε). The amino acid sequence of human CD3ε is set forth in UniProt (www.uniprot.org) entry P07766 (version 202). In another aspect, the CD3 is cynomolgus monkey (Macaca fascicularis) CD3, particularly cynomolgus monkey CD3ε. The amino acid sequence of cynomolgus monkey CD3ε is shown in NCBI GenBank No. BAB71849.1. In certain embodiments, T cell activators useful in the present invention bind to an epitope of CD3 that is conserved between CD3 antigens from different species, particularly human and cynomolgus monkey CD3. In a preferred embodiment, the T cell activator binds to human CD3.
[0065] A "modification that promotes association between a first subunit and a second subunit of an Fc domain" refers to manipulation of the peptide backbone or post-translational modification of an Fc domain subunit that reduces or prevents association of a polypeptide comprising the Fc domain subunit with an identical polypeptide to form a homodimer. As used herein, a modification that promotes association preferably includes separate alterations made to each of the two Fc domain subunits (i.e., the first and second Fc domain subunits) that are desired to associate, where the modifications are complementary to each other to promote association of the two Fc domain subunits. For example, a modification that promotes association may alter the structure or charge of one or both of the Fc domain subunits to achieve the desired steric or electrostatic association, respectively. Thus, (hetero)dimerization can occur between a polypeptide comprising a first Fc domain subunit and a polypeptide comprising a second Fc domain subunit, and the subunits may not be identical, in the sense that the additional components (e.g., antigen-binding domains) fused to each of the subunits are not identical. In some embodiments, the modification that promotes association between the first and second subunits of the Fc domain comprises an amino acid mutation, specifically an amino acid substitution, within the Fc domain. In preferred embodiments, the modification that promotes association between the first and second subunits of the Fc domain comprises a separate amino acid mutation, specifically an amino acid substitution, in each of the two subunits of the Fc domain.
[0066] The term "effector function" refers to a biological activity attributable to the Fc region of an antibody and varies with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen-presenting cells, down-regulation of cell surface receptors (e.g., B cell receptors), and B cell activation.
[0067] An "activating Fc receptor" is an Fc receptor that, upon engagement by the Fc domain of an antibody, triggers signaling events that stimulate the receptor-containing cell to exert effector function. Human activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). In one embodiment, the activating Fc receptor is FcγRIIIa (CD16a). Human FcγRIIIa (CD16a), including its sequence, is described in UniProt entry P08637 (version 203).
[0068] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that causes immune effector cells to lyse antibody-coated target cells. Target cells are cells to which an antibody or its derivative, including an Fc region, specifically binds, typically via a protein portion N-terminal to the Fc region. As used herein, the term "reduced ADCC" is defined as either a reduction in the number of target cells lysed in a given time period with a given concentration of antibody in the medium surrounding the target cells, via the ADCC mechanism defined above, and / or an increase in the concentration of antibody in the medium surrounding the target cells required to achieve lysis of a given number of target cells in a given time period via the ADCC mechanism. Reduced ADCC is compared to unengineered ADCC mediated by the same antibody produced by the same type of host cell using the same standard production, purification, formulation, and storage methods (known to those skilled in the art). For example, an amino acid substitution that reduces ADCC mediated by an antibody containing its Fc domain is relative to ADCC mediated by the same antibody without this amino acid substitution in the Fc domain. Suitable assays for measuring ADCC are well known in the art (see, for example, PCT Application WO 2006 / 082515 or PCT Application WO 2012 / 130831).
[0069] As used herein, the terms "engineer," "engineered," and "manipulating" are intended to include any manipulation or post-translational modification of the peptide backbone of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering includes modifying the amino acid sequence, modifying the glycosylation pattern, or modifying the side groups of individual amino acids, as well as combinations of these approaches.
[0070] The term "amino acid mutation" as used herein is intended to encompass amino acid substitution, deletion, insertion, and modification. Any combination of substitution, deletion, insertion, and modification can be performed to arrive at a final construct, as long as the final construct has the desired characteristics, such as reduced binding to an Fc receptor or increased association with another peptide. Deletions and insertions in the amino acid sequence include deletions and insertions of amino and / or carboxy terminal amino acids. Preferred amino acid mutations are amino acid substitutions. For example, for the purpose of altering the binding characteristics of the Fc region, non-conservative amino acid substitutions, i.e., replacing one amino acid with another amino acid with different structural and / or chemical properties, are particularly preferred. Amino acid substitutions include substitutions with unnatural amino acids or naturally occurring amino acid derivatives of the 20 standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, etc. It is contemplated that methods other than genetic engineering to alter the side chain group of an amino acid, such as chemical modification, may also be useful. Various names may be used herein to refer to the same amino acid mutation. For example, a proline to glycine substitution at position 329 in the Fc domain is referred to as 329G, G329, G 329 , P329G or Pro329Gly.
[0071] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to those in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment to determine percent amino acid sequence identity can be accomplished in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software, or the FASTA program package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment across the entire length of the sequences being compared. Alternatively, percent identity values can be generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code is on file in the user documentation section of the U.S. Copyright Office, Washington, DC 20559, registered under U.S. Copyright Registration No. TXU510087, and described in WO 2001 / 007611.
[0072] Unless otherwise specified, for purposes herein, percent amino acid sequence identity values are generated using the ggsearch program of the FASTA package version 36.3.8c, followed by the BLOSUM50 comparison matrix. The FASTA program package was created by W.R. Pearson and D.J. Lipman ("Improved Tools for Biological Sequence Analysis", PNAS 85(1988):2444-2448), W.R. Pearson ("Effective protein sequence comparison", Meth. Enzymol. 266(1996):227-258), and Pearson et al. (Genomics 46(1997)24-36), and is publicly available at www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, sequences can be compared using the public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi using the ggsearch(global protein:protein) program and default options (BLOSUM50; open:-10; ext:-2; Ktup=2), ensuring a global rather than local alignment. The percent amino acid identity is given in the output alignment header.
[0073] The terms "polynucleotide" or "nucleic acid molecule" include any compound and / or substance comprising a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Nucleic acid molecules are often described by their base sequence, where the bases represent the primary (linear) structure of the nucleic acid molecule. The sequence of bases is typically represented 5' to 3'. As used herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), particularly messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers containing two or more of these molecules. Nucleic acid molecules may be linear or circular. Additionally, the term nucleic acid molecule encompasses both sense and antisense strands, and both single- and double-stranded forms. Furthermore, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides, including those containing derivatized sugar or phosphate backbone linkages or chemically modified residues, include modified nucleotide bases. Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct expression of the antibodies of the present invention in vitro and / or in vivo, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and / or expression of the encoded molecule, such that the mRNA can be injected into a subject to generate antibodies in vivo (see, e.g., Stadler et al. (2017) Nature Medicine 23:815-817, or EP 2 101 823 B1).
[0074] An "isolated" nucleic acid molecule refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid molecules include nucleic acid molecules contained within cells that normally contain the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its native chromosomal location.
[0075] An "isolated polynucleotide (or nucleic acid) encoding an antibody" refers to one or more polynucleotide molecules that encode the heavy and light chains (or fragments thereof) of an antibody, including such polynucleotide molecule(s) in a single vector or separate vectors, where such polynucleotide molecule(s) are present in one or more locations in a host cell.
[0076] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. This term includes vectors as autonomously replicating nucleic acid structures as well as vectors that are integrated into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."
[0077] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," and include the primary transformed cell and progeny derived from the host cell, regardless of the number of passages. Progeny may not have exactly the same nucleic acid content as the parent cell, but may contain mutations. Included herein are progeny of mutants that have the same function or biological activity as screened or selected for in the originally transformed cell. Host cells are any type of cell line that can be used to produce antibodies of the invention. Host cells include cultured cells, e.g., cultured mammalian cells, such as HEK cells, CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells, or hybridoma cells, to name a few, yeast cells, insect cells, and plant cells, but also include cells contained in transgenic animals, transgenic plants, or cultured plant or animal tissue. In one aspect, the host cell of the invention is a eukaryotic cell, in particular a mammalian cell. In one aspect, the host cell is not a cell in the human body.
[0078] The term "pharmaceutical composition" or "pharmaceutical formulation" refers to a preparation that is in a form such that the biological activity of the active ingredient contained in the preparation is effective and that does not contain any additional ingredients that are unacceptably toxic to a subject to whom the composition will be administered.
[0079] A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition or formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0080] As used herein, "treatment" (and its grammatical variants, e.g., "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of disease in the individual being treated, and can be carried out prophylactically or during the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, remission or palliation of disease symptoms, and recovery or improved prognosis. In some aspects, the antibodies of the invention are used to delay the onset of disease or to slow the progression of disease.
[0081] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, the individual or subject is human.
[0082] An "effective amount" of an agent, eg, a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic or prophylactic result.
[0083] The term "package insert" is used to refer to instructions typically included in commercial packaging for a therapeutic product, and includes information regarding the indications, uses, dosage, administration, concomitant therapy, contraindications and / or warnings regarding such therapeutic product.
[0084] II. Compositions and Methods The present invention provides antibodies that bind to NKG2D, including multispecific antibodies that bind to NKG2D and a second antigen. The antibodies exhibit excellent binding and agonistic activity to NKG2D, combined with other favorable properties for therapeutic applications, e.g., with respect to efficacy and safety, pharmacokinetics, and productivity. The antibodies of the present invention are useful, for example, in the treatment of diseases such as cancer.
[0085] The antibodies of the present invention are particularly useful for (co)stimulating cytotoxic T cells in combination with T cell activators, such as T cell bispecific antibodies (TCBs). The antibodies of the present invention can also efficiently activate other NKG2D-expressing immune cells, such as natural killer (NK) cells and γδ T cells, without the need for costimulation via activating Fc receptors, such as FcγRIIIa (CD16a). By avoiding the need for Fc receptor binding and activation for their function, the antibodies of the present invention are believed to enable efficient immune cell activation with a lower risk of systemic side effects than NKG2D antibodies that require Fc receptor binding and activation for their function. The antibodies of the present invention can also be used in a multispecific format that binds to NKG2D and target cell antigens (e.g., tumor antigens) to achieve targeted immune cell activation, but does not bind to activating Fc receptors (particularly FcγRIIIa (CD16a)) to reduce the risk of systemic side effects.
[0086] A. Anti-NKG2D antibody The present invention provides antibodies that bind to NKG2D.
[0087] In a first aspect, the present invention provides an antibody that binds to NKG2D, comprising: (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 selected from the group consisting of SEQ ID NO: 74, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, and SEQ ID NO: 105, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78; (ii) a VH comprising an HCDR1 of SEQ ID NO: 65, an HCDR2 of SEQ ID NO: 66, and an HCDR3 of SEQ ID NO: 67, and a VL comprising an LCDR1 of SEQ ID NO: 68, an LCDR2 of SEQ ID NO: 69, and an LCDR3 of SEQ ID NO: 70; (iii) a VH comprising an HCDR1 of SEQ ID NO: 1, an HCDR2 of SEQ ID NO: 2, and an HCDR3 of SEQ ID NO: 3, and a VL comprising an LCDR1 of SEQ ID NO: 4, an LCDR2 of SEQ ID NO: 5, and an LCDR3 of SEQ ID NO: 6; (iv) a VH comprising an HCDR1 of SEQ ID NO: 25, an HCDR2 of SEQ ID NO: 26, and an HCDR3 of SEQ ID NO: 27, and a VL comprising an LCDR1 of SEQ ID NO: 28, an LCDR2 of SEQ ID NO: 29, and an LCDR3 of SEQ ID NO: 30; (v) a VH comprising an HCDR1 of SEQ ID NO: 49, an HCDR2 of SEQ ID NO: 50, and an HCDR3 of SEQ ID NO: 51, and a VL comprising an LCDR1 of SEQ ID NO: 52, an LCDR2 of SEQ ID NO: 53, and an LCDR3 of SEQ ID NO: 54; (vi) a VH comprising an HCDR1 of SEQ ID NO: 57, an HCDR2 of SEQ ID NO: 58, and an HCDR3 of SEQ ID NO: 59, and a VL comprising an LCDR1 of SEQ ID NO: 60, an LCDR2 of SEQ ID NO: 61, and an LCDR3 of SEQ ID NO: 62; (vii) a VH comprising an HCDR1 of SEQ ID NO: 9, an HCDR2 of SEQ ID NO: 10, and an HCDR3 of SEQ ID NO: 11, and a VL comprising an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 13, and an LCDR3 of SEQ ID NO: 14; (viii) VH comprising an HCDR1 of SEQ ID NO: 17, an HCDR2 of SEQ ID NO: 18, and an HCDR3 of SEQ ID NO: 19, and VL comprising an LCDR1 of SEQ ID NO: 20, an LCDR2 of SEQ ID NO: 21, and an LCDR3 of SEQ ID NO: 22; (ix) a VH comprising an HCDR1 of SEQ ID NO: 33, an HCDR2 of SEQ ID NO: 34, and an HCDR3 of SEQ ID NO: 35, and a VL comprising an LCDR1 of SEQ ID NO: 36, an LCDR2 of SEQ ID NO: 37, and an LCDR3 of SEQ ID NO: 38; or (x) An antibody is provided, comprising a first antigen-binding domain comprising a VH comprising an HCDR1 of SEQ ID NO: 41, an HCDR2 of SEQ ID NO: 42, and an HCDR3 of SEQ ID NO: 43, and a VL comprising an LCDR1 of SEQ ID NO: 44, an LCDR2 of SEQ ID NO: 45, and an LCDR3 of SEQ ID NO: 46.
[0088] In one aspect, the present invention provides an antibody that binds to NKG2D, comprising: (i) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, and / or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:80; (ii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 71, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 72; (iii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 7, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 8; (iv) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 31, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 32; (v) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 55, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 56; (vi) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 63, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 64; (vii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 15, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 16; (viii) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 23, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 24; (ix) a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 39, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 40; or (x) an antibody comprising a first antigen-binding domain comprising a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 47, and / or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 48.
[0089] In one aspect, the antibody The first antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 selected from the group consisting of SEQ ID NO: 74, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, and SEQ ID NO: 105, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78.
[0090] In one aspect, the antibody The first antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 74, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78.
[0091] In one aspect, the antibody The first antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 102, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78.
[0092] In certain embodiments, the antibody comprises: The first antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 104, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78.
[0093] In one embodiment, the antibody is a humanized antibody. In one embodiment, the antigen-binding domain is a humanized antigen-binding domain (i.e., the antigen-binding domain of a humanized antibody). In one embodiment, the VH and / or VL are humanized variable regions. In one embodiment, the VH is a humanized variable region and the VL is a human variable region.
[0094] In one aspect, the VH and / or VL comprise an acceptor human framework, such as a human immunoglobulin framework or a human consensus framework.
[0095] In one aspect, the VH comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3 and / or FR4 sequences) of a heavy chain variable region sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a heavy chain variable region sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly the heavy chain variable region sequence of SEQ ID NO:112. In one aspect, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly an amino acid sequence that is at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:112. In one aspect, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:112. In one aspect, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:112.In certain embodiments, a VH sequence having at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to a reference sequence, but antibodies comprising the sequence retain the ability to bind to NKG2D. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, and SEQ ID NO:113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, and SEQ ID NO:113, most particularly the amino acid sequence of SEQ ID NO:112. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one aspect, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 79, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112 and SEQ ID NO: 113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112 and SEQ ID NO: 113, most particularly the amino acid sequence of SEQ ID NO: 112. Optionally, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 79, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112 and SEQ ID NO: 113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112 and SEQ ID NO: 113, most particularly the amino acid sequence of SEQ ID NO: 112, including post-translational modifications of said sequence.
[0096] In one embodiment, the VL comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO: 80. In one embodiment, the VL comprises an amino acid sequence at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence of SEQ ID NO: 80. In one embodiment, the VL comprises an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 80. In one embodiment, the VL comprises an amino acid sequence at least about 98% identical to the amino acid sequence of SEQ ID NO: 80. In certain embodiments, a VL sequence with at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, although antibodies comprising the sequence retain the ability to bind to NKG2D. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 80. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 80. Optionally, the VL comprises the amino acid sequence of SEQ ID NO: 80, including post-translational modifications of that sequence.
[0097] In one aspect, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:112, and the VL comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:80. In one aspect, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly the amino acid sequence of SEQ ID NO:112, and the VL comprises the amino acid sequence of SEQ ID NO:80.
[0098] In a further aspect, the present invention provides an antibody that binds to NKG2D, comprising a first antigen-binding domain comprising a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly an amino acid sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly the amino acid sequence of SEQ ID NO:112, and a VL comprising the amino acid sequence of SEQ ID NO:80.
[0099] In a further aspect, the present invention provides an antibody that binds to NKG2D, wherein the antibody comprises a first antigen-binding domain comprising a VH sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH sequence selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly the VH sequence of SEQ ID NO:112 and the VL sequence of SEQ ID NO:80.
[0100] In another aspect, the invention provides an antibody that binds to NKG2D, comprising a first antigen-binding domain comprising a VH selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO:112, and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO:80.
[0101] In a further aspect, the first antigen-binding domain comprises a VH selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the VH of SEQ ID NO:112 and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the VL of SEQ ID NO:11.
[0102] In one aspect the VH comprises the heavy chain CDR sequences of a VH selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly a VH of SEQ ID NO:112, and A VH selected from the group consisting of SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112 and SEQ ID NO: 113, more particularly a VH selected from the group consisting of SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112 and SEQ ID NO: 113, most particularly comprising a framework having at least about 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VH of SEQ ID NO: 112. In one aspect the VH comprises the heavy chain CDR sequences of a VH selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly a VH of SEQ ID NO:112 and a framework of at least about 95% sequence identity to the framework sequence of a VH selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly a VH of SEQ ID NO:112.In another aspect, the VH comprises the heavy chain CDR sequences of a VH selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly a VH of SEQ ID NO:112 and a framework of at least about 98% sequence identity to the framework sequence of a VH selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, more particularly a VH selected from the group consisting of SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, most particularly a VH of SEQ ID NO:112.
[0103] In one aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 80 and a framework of at least 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VL of SEQ ID NO: 80. In one aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 80 and a framework of at least 95% sequence identity to the framework sequence of the VL of SEQ ID NO: 80. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 80 and a framework of at least 98% sequence identity to the framework sequence of the VL of SEQ ID NO: 80.
[0104] In one aspect, the antibody It comprises a first antigen-binding domain comprising a VH comprising an HCDR1 of SEQ ID NO: 65, an HCDR2 of SEQ ID NO: 66, and an HCDR3 of SEQ ID NO: 67, and a VL comprising an LCDR1 of SEQ ID NO: 68, an LCDR2 of SEQ ID NO: 69, and an LCDR3 of SEQ ID NO: 70.
[0105] In one embodiment, the antibody is a human antibody. In one embodiment, the antigen-binding domain is a human antigen-binding domain (i.e., the antigen-binding domain of a human antibody). In one embodiment, VH and / or VL are human variable regions.
[0106] In one embodiment, the VH and / or VL comprise a human framework, such as a human immunoglobulin framework.
[0107] In one aspect, the VH comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3 and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO: 71. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence of SEQ ID NO: 71. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 71. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO: 71. In certain aspects, a VH sequence that is at least about 95%, about 96%, about 97%, about 98%, or about 99% identical contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, although antibodies comprising that sequence retain the ability to bind to NKG2D. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 71. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 71. Optionally, the VH comprises the amino acid sequence of SEQ ID NO: 71, including post-translational modifications of that sequence.
[0108] In one embodiment, the VL comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO: 72. In one embodiment, the VL comprises an amino acid sequence at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence of SEQ ID NO: 72. In one embodiment, the VL comprises an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 72. In one embodiment, the VL comprises an amino acid sequence at least about 98% identical to the amino acid sequence of SEQ ID NO: 72. In certain embodiments, a VL sequence with at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, although antibodies comprising the sequence retain the ability to bind to NKG2D. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 72. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 72. Optionally, the VL comprises the amino acid sequence of SEQ ID NO: 72, including post-translational modifications of that sequence.
[0109] In one aspect, the VH comprises an amino acid sequence at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71, and the VL comprises an amino acid sequence at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72. In one aspect, the VH comprises the amino acid sequence of SEQ ID NO: 71, and the VL comprises the amino acid sequence of SEQ ID NO: 72.
[0110] In a further aspect, the present invention provides an antibody that binds to NKG2D, comprising a first antigen-binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 72.
[0111] In a further aspect, the invention provides an antibody that binds to NKG2D, the antibody comprising a first antigen-binding domain comprising the VH sequence of SEQ ID NO:71 and the VL sequence of SEQ ID NO:72.
[0112] In another aspect, the invention provides an antibody that binds to NKG2D, comprising a first antigen-binding domain comprising a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 71 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 72.
[0113] In a further aspect, the first antigen-binding domain comprises the VH HCDR1, HCDR2 and HCDR3 amino acid sequences of SEQ ID NO: 71 and the VL LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NO: 72.
[0114] In one aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 71 and a framework of at least 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VH of SEQ ID NO: 71. In one aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 71 and a framework of at least 95% sequence identity to the framework sequence of the VH of SEQ ID NO: 71. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 71 and a framework of at least 98% sequence identity to the framework sequence of the VH of SEQ ID NO: 71.
[0115] In one aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 72 and a framework of at least 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VL of SEQ ID NO: 72. In one aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 72 and a framework of at least 95% sequence identity to the framework sequence of the VL of SEQ ID NO: 72. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 72 and a framework of at least 98% sequence identity to the framework sequence of the VL of SEQ ID NO: 72.
[0116] In one aspect, the antibody It comprises a first antigen-binding domain comprising a VH comprising an HCDR1 of SEQ ID NO: 1, an HCDR2 of SEQ ID NO: 2, and an HCDR3 of SEQ ID NO: 3, and a VL comprising an LCDR1 of SEQ ID NO: 4, an LCDR2 of SEQ ID NO: 5, and an LCDR3 of SEQ ID NO: 6.
[0117] In one embodiment, the antibody is a human antibody. In one embodiment, the antigen-binding domain is a human antigen-binding domain (i.e., the antigen-binding domain of a human antibody). In one embodiment, VH and / or VL are human variable regions.
[0118] In one embodiment, the VH and / or VL comprise a human framework, such as a human immunoglobulin framework.
[0119] In one embodiment, the VH comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO: 7. In one embodiment, the VH comprises an amino acid sequence that is at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence of SEQ ID NO: 7. In one embodiment, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 7. In one embodiment, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO: 7. In certain embodiments, VH sequences that are at least about 95%, about 96%, about 97%, about 98%, or about 99% identical contain substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, although antibodies comprising such sequences retain the ability to bind to NKG2D. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 7. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 7. Optionally, the VH comprises the amino acid sequence of SEQ ID NO: 7, including post-translational modifications of that sequence.
[0120] In one embodiment, the VL comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO: 8. In one embodiment, the VL comprises an amino acid sequence at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence of SEQ ID NO: 8. In one embodiment, the VL comprises an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 8. In one embodiment, the VL comprises an amino acid sequence at least about 98% identical to the amino acid sequence of SEQ ID NO: 8. In certain embodiments, a VL sequence with at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, although antibodies comprising the sequence retain the ability to bind to NKG2D. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 8. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 8. Optionally, the VL comprises the amino acid sequence of SEQ ID NO: 8, including post-translational modifications of that sequence.
[0121] In one aspect, the VH comprises an amino acid sequence at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 7, and the VL comprises an amino acid sequence at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 8. In one aspect, the VH comprises the amino acid sequence of SEQ ID NO: 7, and the VL comprises the amino acid sequence of SEQ ID NO: 8.
[0122] In a further aspect, the present invention provides an antibody that binds to NKG2D, comprising a first antigen-binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO:7 and a VL comprising the amino acid sequence of SEQ ID NO:8.
[0123] In a further aspect, the invention provides an antibody that binds to NKG2D, the antibody comprising a first antigen-binding domain comprising the VH sequence of SEQ ID NO:7 and the VL sequence of SEQ ID NO:8.
[0124] In another aspect, the invention provides an antibody that binds to NKG2D, comprising a first antigen-binding domain comprising a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 7 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 8.
[0125] In a further aspect, the first antigen-binding domain comprises the VH HCDR1, HCDR2 and HCDR3 amino acid sequences of SEQ ID NO:7 and the VL LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NO:8.
[0126] In one aspect the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 7 and a framework of at least 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VH of SEQ ID NO: 7. In one aspect the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 7 and a framework of at least 95% sequence identity to the framework sequence of the VH of SEQ ID NO: 7. In another aspect the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 7 and a framework of at least 98% sequence identity to the framework sequence of the VH of SEQ ID NO: 7.
[0127] In one aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 8 and a framework of at least 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VL of SEQ ID NO: 8. In one aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 8 and a framework of at least 95% sequence identity to the framework sequence of the VL of SEQ ID NO: 8. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 8 and a framework of at least 98% sequence identity to the framework sequence of the VL of SEQ ID NO: 8.
[0128] In one aspect, the invention provides an antibody that binds to NKG2D, the antibody comprising a first antigen-binding domain comprising a VH sequence of any of the aspects provided above and a VL sequence of any of the aspects provided above.
[0129] In one embodiment, the antibody comprises a human constant region. In one embodiment, the antibody is an immunoglobulin molecule comprising a human constant region, particularly an IgG class immunoglobulin molecule comprising human CH1, CH2, CH3 and / or CL domains. Exemplary sequences of human constant domains are given in SEQ ID NOs: 83 and 84 (human kappa and lambda CL domains, respectively), and SEQ ID NO: 85 (human IgG1 heavy chain constant domain CH1-CH2-CH3). In one embodiment, the antibody comprises a light chain constant region comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 83 or SEQ ID NO: 84, particularly the amino acid sequence of SEQ ID NO: 83. In one embodiment, the antibody comprises a heavy chain constant region comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 85. In particular, the heavy chain constant region may comprise amino acid mutations in the Fc domain described herein.
[0130] In one embodiment, the first antigen-binding domain comprises a human constant region. In one embodiment, the first antigen-binding moiety is a Fab molecule comprising a human constant region, particularly a human CH1 and / or CL domain. In one embodiment, the first antigen-binding domain comprises a light chain constant region comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 83 or SEQ ID NO: 84, particularly the amino acid sequence of SEQ ID NO: 83. In particular, the light chain constant region may comprise amino acid mutations described herein in a "charge-modified" state and / or, in the case of a crossover Fab molecule, deletion or substitution of one or more (particularly two) N-terminal amino acids. In some embodiments, the first antigen-binding domain comprises a heavy chain constant region comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the CH1 domain sequence contained in the amino acid sequence of SEQ ID NO: 85. In particular, the heavy chain constant region (specifically the CH1 domain) may comprise the amino acid mutations described herein in a "charge-modified" state.
[0131] In one embodiment, the antibody is a monoclonal antibody.
[0132] In one embodiment the antibody is an IgG, in particular an IgG1 antibody. In one embodiment the antibody is a full-length antibody.
[0133] In another embodiment, the antibody is an antibody fragment, particularly a Fab molecule, selected from the group of Fv, scFv, Fab, and F(ab')2 molecules. In another embodiment, the antibody fragment is a diabody, triabody, or tetrabody.
[0134] The first antigen-binding domain contained in the antibody according to the present invention binds to NKG2D.
[0135] In preferred embodiments, the antibody comprises no more than one antigen-binding domain that binds to NKG2D. In one embodiment, the antibody provides monovalent binding to NKG2D. In another embodiment, the antibody comprises two or more (e.g., two, three, or four) antigen-binding domains that bind to NKG2D. In one embodiment, the antibody provides multivalent binding to NKG2D. In one embodiment, the antibody comprises two antigen-binding domains that bind to NKG2D. In one embodiment, the antibody provides bivalent binding to NKG2D. In another embodiment, the antibody comprises four antigen-binding domains that bind to NKG2D. In one embodiment, the antibody provides tetravalent binding to NKG2D.
[0136] In embodiments in which the antibody comprises two or more antigen-binding domains that bind to NKG2D, preferably all of these antigen-binding domains are identical, i.e., they have the same molecular format (e.g., a conventional Fab molecule or a crossover Fab molecule) and comprise the same amino acid sequence.
[0137] In another embodiment, the first antigen-binding domain is an antibody fragment selected from the group of an Fv molecule, an scFv molecule, an Fab molecule, and an F(ab')2 molecule.
[0138] In one embodiment, the first antigen-binding domain is a Fab molecule. In a preferred embodiment, the first antigen-binding moiety is a Fab molecule in which the variable domains VL and VH or the constant domains CL and CH1, in particular the variable domains VL and VH, of the Fab light chain and the Fab heavy chain are replaced by each other (i.e., the first antigen-binding domain is a crossover Fab molecule).
[0139] In further embodiments, antibodies according to any of the above embodiments can incorporate any of the features, alone or in combination, as described in Sections II.A.1.-10. below.
[0140] In a preferred embodiment, the antibody comprises an Fc domain, particularly an IgG Fc domain, more particularly an IgG1 Fc domain. In one embodiment, the Fc domain is a human Fc domain. In one embodiment, the Fc domain is a human IgG1 Fc domain. The Fc domain is composed of a first subunit and a second subunit and may incorporate, alone or in combination, any of the features described herein below (Section II.A.10.) in relation to Fc domain variants.
[0141] In another preferred embodiment, the antibody comprises a second antigen-binding domain that binds to a second antigen (i.e., the antibody is a multispecific antibody, as further described herein below (Section II.A.9.)).
[0142] 1. Antibody fragment In certain aspects, the antibodies provided herein are antibody fragments.
[0143] In one embodiment, the antibody fragment is a Fab molecule, a Fab' molecule, a Fab'-SH molecule, or a F(ab')2 molecule, particularly a Fab molecule as described herein. A "Fab' molecule" differs from a Fab molecule only by the addition of residues at the carboxy terminus of the CH1 domain that contain one or more cysteines from the antibody hinge region. Fab'-SH is a Fab' molecule in which the cysteine residue(s) in the constant domains bear a free thiol group. Pepsin treatment yields an F(ab')2 molecule that has two antigen-binding sites (two Fab molecules) and a portion of the Fc region.
[0144] In another embodiment, the antibody fragment is a diabody, triabody, or tetrabody. Diabodies are antibody fragments with two antigen-binding sites, which may be bivalent or bispecific. See, e.g., EP 404,097, WO 1993 / 01161, Hudson et al., Nat. Med. 9:129-134 (2003), and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
[0145] In a further embodiment, the antibody fragment is a single-chain Fab molecule. A "single-chain Fab molecule" or "scFab" is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody heavy chain constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, where the antibody domains and the linker have one of the following orders, from N- to C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL. In particular, the linker is a polypeptide of at least 30 amino acids, preferably 32-50 amino acids. Single-chain Fab molecules are stabilized by a native disulfide bond between the CL and CH1 domains. In addition, these single-chain Fab molecules may be further stabilized by the creation of interchain disulfide bonds through the insertion of cysteine residues (e.g., at position 44 of the variable heavy chain and position 100 of the variable light chain according to Kabat numbering).
[0146] In another embodiment, the antibody fragment is a single-chain variable fragment (scFv). A "single-chain variable fragment" or "scFv" is a fusion protein of the variable domains of an antibody's heavy chain (VH) and light chain (VL) connected by a linker. In particular, the linker is a short polypeptide of 10 to 25 amino acids, typically rich in glycine for flexibility and serine or threonine for solubility, that can connect the N-terminus of VH to the C-terminus of VL, or vice versa. This protein can retain the specificity of the original antibody despite the removal of the constant regions and the introduction of the linker. For a review of scFv fragments, see, for example, Plueckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994), as well as WO 93 / 16185, and U.S. Pat. Nos. 5,571,894 and 5,587,458.
[0147] In another embodiment, the antibody fragment is a single-domain antibody. A "single-domain antibody" is an antibody fragment that comprises all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc. Waltham, Massachusetts; see, e.g., U.S. Patent No. 6,248,516 B1).
[0148] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and recombinant production in recombinant host cells (e.g., E. coli), as described herein.
[0149] 2. Chimeric and humanized antibodies In certain embodiments, the antibodies provided herein are chimeric antibodies. Certain chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
[0150] In certain aspects, the antibodies provided herein are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity in humans while retaining the specificity and affinity of the parent non-human antibody. Usually, a humanized antibody comprises one or more variable domains in which the CDRs (or portions thereof) are derived from a non-human antibody, and the FRs (or portions thereof) are derived from human antibody sequences. Optionally, the humanized antibody also comprises at least a portion of a human constant region. In some aspects, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve antibody specificity or affinity.
[0151] Humanized antibodies and methods for their production are reviewed by Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (description of specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (description of resurfacing); Dall'Acqua et al., Methods 36:43-60 (2005) (description of FR shuffling); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (description of a "guided selection approach" for FR shuffling).
[0152] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)), framework regions derived from consensus sequences of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992) and Presta et al. J. Immunol., 151:2623 (1993)), human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)), and framework regions derived from screening of FR libraries (see, e.g., Baca et al. al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).
[0153] 3. Human antibodies In certain embodiments, the antibodies provided herein are human antibodies. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
[0154] Human antibodies can be prepared by administering immunogens to transgenic animals that have been engineered to produce intact human antibodies or intact antibodies with human variable regions in response to antigen challenge. Such animals typically contain all or part of human immunoglobulin loci that replace endogenous immunoglobulin loci, or that are present extrachromosomally or randomly integrated into the animal's chromosomes. In such transgenic animals, the endogenous immunoglobulin loci are generally inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584, which describe XENOMOUSE™ technology; U.S. Patent No. 5,770,429, which describes HuMab® technology; U.S. Patent No. 7,041,870, which describes KM MOUSE® technology; and U.S. Patent Application Publication No. 2007 / 0061900, which describes VelociMouse® technology. The human variable regions from intact antibodies produced by such animals may be further modified, for example, by combining with different human constant regions.
[0155] Human antibodies can also be produced by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described (see, e.g., Kozbor J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147:86 (1991)). Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Further methods are described, for example, in U.S. Pat. No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai. Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (trioma technology) is also described in Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).
[0156] Human antibodies can also be generated by isolating variable domain sequences selected from human-derived phage display libraries. These variable domain sequences can then be combined with desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.
[0157] 4. Library-derived antibodies In certain embodiments, the antibodies provided herein are obtained from libraries.The antibodies of the present invention can be isolated by screening combinatorial libraries for antibodies with one or more desired activities.Methods for screening combinatorial libraries are, for example, reviewed in Lerner et al., Nature Reviews 16:498-508 (2016).For example, various methods are known in the art for generating phage display libraries and screening such libraries for antibodies with desired binding properties. Such methods are reviewed, for example, in Frenzel et al., mAbs 8:1177-1194 (2016); Bazan et al., Human Vaccines and Immunotherapeutics 8:1817-1828 (2012) and Zhao et al., Critical Reviews in Biotechnology 36:276-289 (2016), as well as Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and Marks and Bradbury, Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003).
[0158] In one particular phage display method, repertoires of VH and VL genes are individually cloned by polymerase chain reaction (PCR) and randomly recombined into phage libraries, which can then be screened for antigen-binding phage, as described in Winter et al., Annual Review of Immunology 12:433-455 (1994). Phage typically display antibody fragments as either single-chain Fv (scFv) fragments or Fab fragments. Libraries from immune sources provide high-affinity antibodies to immunogens without the need to construct hybridomas. Alternatively, naive repertoires can be cloned (e.g., from humans), providing a single source of antibodies against a wide range of non-self and even self antigens without immunization, as described by Griffiths et al., EMBO Journal 12:725-734 (1993). Finally, naive libraries can also be synthetically generated by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and achieve reordering in vitro, as described by Hoogenboom and Winter in Journal of Molecular Biology 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Patent Nos. 5,750,373, 7,985,840, 7,785,903, and 8,679,490, as well as U.S. Patent Application Publication Nos. 2005 / 0079574, 2007 / 0117126, 2007 / 0237764, and 2007 / 0292936.
[0159] Further examples of methods known in the art for screening combinatorial libraries for antibodies with one or more desired activities include ribosome and mRNA display, as well as methods for antibody display and selection in bacteria, mammalian cells, insect cells, or yeast cells. Methods for yeast surface display are reviewed, for example, in Scholler et al., Methods in Molecular Biology 503:135-56 (2012), Cherf et al., Methods in Molecular Biology 1319:155-175 (2015), and Zhao et al., Methods in Molecular Biology 889:73-84 (2012). Methods for ribosome display are described, for example, in He et al., Nucleic Acids Research 25:5132-5134 (1997) and Hanes et al., PNAS 94:4937-4942 (1997).
[0160] Antibodies or antibody fragments isolated from a human antibody library are considered human antibodies or human antibody fragments herein.
[0161] 5. Glycosylation Mutants In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent of glycosylation of the antibody. Addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.
[0162] If the antibody contains an Fc region, the oligosaccharides attached to the antibody may be altered. Native antibodies produced by mammalian cells typically contain branched, biantennary oligosaccharides that are commonly attached to Asn297 in the CH2 domain of the Fc region via an N-linkage. See, e.g., Wright et al., TIBTECH 15:26-32 (1997). The oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to the GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharides in the antibodies of the present invention may be performed to generate antibody variants with certain improved properties.
[0163] In one embodiment, antibody variants are provided that have nonfucosylated oligosaccharides, i.e., oligosaccharide structures lacking fucose linkage (direct or indirect) to the Fc region. Such nonfucosylated oligosaccharides (also referred to as "afucosylated" oligosaccharides) are particularly N-linked oligosaccharides lacking the first GlcNAc-linked fucose residue at the stem of the biantennary oligosaccharide structure. In one embodiment, antibody variants are provided that have an increased proportion of nonfucosylated oligosaccharides in the Fc region compared to the native or parent antibody. For example, the proportion of nonfucosylated oligosaccharides can be at least about 20%, at least about 40%, at least about 60%, at least about 80%, or even about 100% (i.e., no fucosylated oligosaccharides present). The percentage of nonfucosylated oligosaccharides is the (average) amount of oligosaccharides lacking a fucose residue relative to the sum of all oligosaccharides (e.g., complex, hybrid, and high mannose structures) attached to Asn297, as determined, for example, by MALDI-TOF mass spectrometry as described in WO 2006 / 082515. Asn297 refers to the asparagine residue located at approximately position 297 of the Fc region (EU numbering of Fc region residues); however, Asn297 may also be located upstream or downstream of position 297, i.e., approximately ±3 amino acids between positions 294 and 300, due to minor antibody sequence variations. Such antibodies with an increased percentage of nonfucosylated oligosaccharides in the Fc region may have improved FcγRIIIa receptor binding and / or improved effector function, particularly improved ADCC function. See, for example, U.S. Patent Application Publication No. 2003 / 0157108; U.S. Patent Application Publication No. 2004 / 0093621.
[0164] Examples of cell lines capable of producing antibodies with reduced fucosylation include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Patent Application Publication No. 2003 / 0157108; and WO 2004 / 056312, especially Example 11), and knockout cell lines, such as FUT8, knockout CHO cells for the alpha-1,6-fucosyltransferase gene (e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87:614-622 (2004); Kanda, Y. et al. al., Biotechnol. Bioeng., 94(4):680-688 (2006); and WO 2003 / 085107), or cells with reduced or abolished activity of GDP-fucose synthesis or transporter proteins (see, e.g., U.S. Patent Application Publication Nos. 2004259150, 2005031613, 2004132140, and 2004110282).
[0165] In a further embodiment, antibody variants are provided with bisected oligosaccharides, e.g., where a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function, as described above. Examples of such antibody variants are described, for example, in Umana et al., Nat Biotechnol 17, 176-180 (1999); Ferrara et al., Biotechn Bioeng 93, 851-861 (2006); WO 99 / 54342; WO 2004 / 065540; and WO 2003 / 011878.
[0166] Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087, WO 1998 / 58964, and WO 1999 / 22764.
[0167] 6. Cysteine Engineered Antibody Variants In certain embodiments, it may be desirable to generate cysteine engineered antibodies, e.g., THIOMAB™, in which one or more residues of an antibody are substituted with cysteine residues. In preferred embodiments, the substituted residues occur at accessible sites on the antibody. By replacing these residues with cysteine, reactive thiol groups are thereby placed at accessible sites on the antibody, which can be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create immunoconjugates, as further described herein. Cysteine engineered antibodies can be generated, for example, as described in U.S. Pat. No. 7,521,541, U.S. Pat. No. 8,30,930, U.S. Pat. No. 7,855,275, U.S. Pat. No. 9,000,130, or WO2016040856.
[0168] 7. Antibody derivatives In certain aspects, the antibodies provided herein may be further modified to contain additional nonproteinaceous moieties known in the art and readily available. Suitable sites for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone), polyethylene glycol, polypropylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may be advantageous during manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody can vary, and when multiple polymers are attached, they can be the same molecule or different molecules. Generally, the number and / or type of polymers used for derivatization can be determined based on considerations such as, but not limited to, the particular property or function of the antibody to be improved and whether the antibody derivative will be used therapeutically under defined conditions.
[0169] 8. Immunoconjugate The present invention also provides immunoconjugates comprising an anti-NKG2D antibody herein conjugated to one or more therapeutic agents, such as a cytotoxic agent, a chemotherapeutic agent or drug, a growth inhibitory agent, a toxin (e.g., a protein toxin, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope.
[0170] In one aspect, the immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more of the aforementioned therapeutic agents. The antibody is typically connected to one or more of the therapeutic agents using a linker. An overview of ADC technology, including examples of therapeutic agents and drugs and linkers, is described in Pharmacol Review 68:3-19 (2016).
[0171] In another embodiment, the immunoconjugate comprises an antibody of the invention conjugated to an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, nonbinding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Jatropha curcas protein, dianthin protein, pokeweed protein (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, soapwort inhibitor, gelonin, mitogenin, restrictocin, phenomycin, enomycin, and the trichothecenes.
[0172] In another embodiment, the immunoconjugate comprises an antibody of the invention conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for the production of radioactive materials. Examples include At 211 , I 131 , I 125 , Y 90 ,Re 186 ,Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 When radioconjugates are used for detection, examples include radioactive atoms for scintigraphy studies, e.g., Tc 99m Or I 123 , or nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), I 123 , I 131 , In 111 , F 19 , C 13 , N 15 , O 17Spin labels such as gadolinium, manganese, or iron may be included.
[0173] Conjugates of antibodies and cytotoxic agents can be prepared using, for example, a variety of bifunctional protein coupling agents: N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bisazide compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and biactive fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See International Publication No. WO 94 / 11026. The linker may also be a "cleavable linker" that facilitates release of the cytotoxic drug within the cell. For example, acid-labile linkers, peptidase-sensitive linkers, photolabile linkers, dimethyl linkers, or disulfide-containing linkers (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Patent No. 5,208,020) can be used.
[0174] The immunoconjugates or ADCs described herein expressly contemplate such conjugates prepared using cross-linking reagents that are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Illinois, USA), including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate).
[0175] 9. Multispecific antibodies In certain embodiments, the antibodies provided herein are multispecific antibodies, particularly bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different antigenic determinants (e.g., two different proteins, or two different epitopes on the same protein). In certain embodiments, multispecific antibodies have three or more binding specificities. In certain embodiments, one binding specificity is for NKG2D and the other is for any other antigen. In certain embodiments, multispecific antibodies can bind to two (or more) different epitopes of NKG2D. Multispecific (e.g., bispecific) antibodies can also be used to localize cytotoxic agents or cells to cells expressing NKG2D. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0176] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature 305:537 (1983)) and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168 and Atwell et al., J. Mol. Biol. 270:26 (1997)). Multispecific antibodies can also be produced by manipulating electrostatic steering effects to create antibody Fc heterodimeric molecules (see, e.g., WO 2009 / 089004); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al., Science, 229:81 (1985)); producing bispecific antibodies using leucine zippers (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992) and WO 2011 / 034605); using conventional light chain technology to circumvent light chain mispairing problems (see, e.g., WO 98 / 50431); using "diabody" technology to create bispecific antibody fragments (see, e.g., Hollinger et al., J. Immunol., 148(5):1547-1553 (1992) and WO 2011 / 034605)). al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and by the use of single-chain Fv (scFv) dimers (see, e.g., Gruber et al., J. Immunol., 152:5368 (1994)); and by the preparation of trispecific antibodies as described, for example, in Tutt et al. J. Immunol. 147:60 (1991).
[0177] Also included herein are engineered antibodies with three or more antigen-binding sites, including, for example, "Octopus antibodies," or DVD-Igs (see, e.g., WO 2001 / 77342 and WO 2008 / 024715). Other examples of multispecific antibodies with three or more antigen-binding sites can be found in WO 2010 / 115589, WO 2010 / 112193, WO 2010 / 136172, WO 2010 / 145792, and WO 2013 / 026831. Multispecific antibodies or antigen-binding fragments thereof also include "dual-acting FAbs" or "DAFs" that contain antigen-binding sites that bind to NKG2D as well as to another different antigen, or to two different epitopes of NKG2D (see, e.g., U.S. Patent Application Publication No. 2008 / 0069820 and WO 2015 / 095539).
[0178] Multispecific antibodies can also be provided in an asymmetric format with domain crossover in one or more binding arms of the same antigen specificity (the so-called "CrossMab" technology), i.e. by exchanging VH / VL domains (see, for example, WO 2009 / 080252 and WO 2015 / 150447), CH1 / CL domains (see, for example, WO 2009 / 080253) or complete Fab arms (see, for example, WO 2009 / 080251, WO 2016 / 016299; see also Schaefer et al., PNAS, 108 (2011) 1187-1191 and Klein at al., MAbs 8 (2016) 1010-20)). Asymmetric Fab arms can also be engineered by introducing charged or uncharged amino acid mutations at the domain interface to direct correct Fab pairing, see, e.g., WO 2016 / 172485.
[0179] A variety of additional molecular formats of multispecific antibodies are known in the art and are included herein (see, e.g., Spiess et al., Mol Immunol 67 (2015) 95-106).
[0180] Preferred embodiments of the multispecific antibodies of the present invention are described below.
[0181] In one aspect, the invention provides an antibody that binds to NKG2D, comprising a first antigen-binding domain that binds to NKG2D as described herein, and a second antigen-binding domain that binds to a second antigen.
[0182] According to a preferred embodiment of the present invention, the antigen-binding domain contained in the antibody is a Fab molecule (i.e., an antigen-binding domain composed of a heavy chain and a light chain, each of which comprises a variable domain and a constant domain). In one embodiment, the first and / or second antigen-binding domain is a Fab molecule. In one embodiment, the Fab molecule is human. In another embodiment, the Fab molecule is humanized. In yet another embodiment, the Fab molecule comprises human heavy and light chain constant domains.
[0183] Preferably, at least one of the antigen-binding domains is a crossover Fab molecule. Such modification reduces mispairing of heavy and light chains of different Fab molecules, thereby improving the yield and purity of the (multispecific) antibodies of the present invention during recombinant production. In preferred crossover Fab molecules useful for the (multispecific) antibodies of the present invention, the variable domains of the Fab light chain and the Fab heavy chain (VL and VH, respectively) are exchanged. However, even with this domain exchange, the preparation of (multispecific) antibodies may contain certain side products due to so-called Bence-Jones type interactions between mispaired heavy and light chains (see Schaefer et al., PNAS, 108 (2011) 11187-11191). To further reduce mispairing of the heavy and light chains of different Fab molecules and thereby increase the purity and yield of the desired (multispecific) antibody, charged amino acids with opposite charges can be introduced into specific amino acid positions in the CH1 and CL domains of either the Fab molecule(s) that bind to the first antigen (NKG2D) or the Fab molecule(s) that bind to the second antigen (e.g., a target cell antigen, e.g., a tumor cell antigen), as further described herein. The charge modifications are made in the conventional Fab molecule(s) (e.g., as shown in Figure 12) comprised in the (multispecific) antibody or in the VH / VL crossover Fab molecule(s) comprised in the (multispecific) antibody, but not both. In a preferred embodiment, the charge modifications are made in the conventional Fab molecule(s) comprised in the (multispecific) antibody (which in a preferred embodiment bind to the second antigen, e.g., a target cell antigen, e.g., a tumor cell antigen).
[0184] In a preferred aspect according to the present invention, the (multispecific) antibody is capable of simultaneously binding to a first antigen (i.e., NKG2D) and a second antigen (e.g., a target cell antigen, e.g., a tumor cell antigen). In one aspect, the (multispecific) antibody is capable of crosslinking an NKG2D-expressing cell (such as a T cell or NK cell) and a target cell (such as a tumor cell) by simultaneously binding to NKG2D and the target cell antigen. In one aspect, such simultaneous binding results in lysis of the target cell, in particular a target cell antigen-expressing tumor cell. In one aspect, such simultaneous binding results in activation of the NKG2D-expressing cell (such as a T cell or NK cell). In another aspect, such simultaneous binding results in a cellular response of the NKG2D-expressing cell (such as a T cell or NK cell) selected from the group of proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. In one embodiment, binding of a (multispecific) antibody to NKG2D without simultaneous binding to a target cell antigen does not result in activation of NKG2D-expressing cells (such as T cells or NK cells).
[0185] In certain of these embodiments, the (multispecific) antibody of the invention is combined with a T cell activator, such as an antibody that binds to CD3, in particular a bispecific antibody that binds to CD3 and to a target cell antigen, in particular a tumor cell antigen.
[0186] Preferably, the T cells according to any embodiment of the invention are cytotoxic T cells. In some embodiments, the T cells are CD8 + In other embodiments, the T cells are γδ T cells.
[0187] a) First antigen-binding domain The (multispecific) antibodies of the present invention comprise at least one antigen-binding domain (first antigen-binding domain) that binds to NKG2D. In preferred embodiments, the NKG2D is human NKG2D or cynomolgus NKG2D, most particularly human NKG2D. In one embodiment, the first antigen-binding domain is cross-reactive with (i.e., binds to) human and cynomolgus NKG2D. In some embodiments, the NKG2D is the extracellular domain of NKG2D.
[0188] In a preferred embodiment, the (multispecific) antibody comprises not more than one antigen-binding domain that binds to NKG2D. In one embodiment, the (multispecific) antibody provides monovalent binding to NKG2D. In another embodiment, the (multispecific) antibody comprises two or more (e.g., two, three, or four) antigen-binding domains that bind to NKG2D. In one embodiment, the (multispecific) antibody provides multivalent binding to NKG2D. In one embodiment, the (multispecific) antibody comprises two antigen-binding domains that bind to NKG2D. In one embodiment, the (multispecific) antibody provides bivalent binding to NKG2D. In another embodiment, the (multispecific) antibody comprises four antigen-binding domains that bind to NKG2D. In one embodiment, the (multispecific) antibody provides tetravalent binding to NKG2D.
[0189] In embodiments in which a (multispecific) antibody comprises two or more antigen-binding domains that bind to NKG2D, preferably all of these antigen-binding domains are identical, i.e., they have the same molecular format (e.g., a conventional Fab molecule or a crossover Fab molecule) and comprise the same amino acid sequence, including (if present) the same amino acid substitutions in the CH1 and CL domains described herein.
[0190] In one embodiment, the antigen-binding domain(s) that bind to NKG2D are antibody fragments selected from the group consisting of Fv, scFv, Fab, and F(ab')2 molecules. In a preferred embodiment, the antigen-binding domain(s) that bind to NKG2D are Fab molecules.
[0191] In some embodiments, the antigen-binding domain(s) that bind to NKG2D are crossover Fab molecules as described herein, i.e., Fab molecules in which the variable domains VH and VL or the constant domains CH1 and CL of the Fab heavy and light chains have been swapped / replaced. In such embodiments, the antigen-binding domain(s) that bind to a second antigen (e.g., a target cell antigen, e.g., a tumor cell antigen) is preferably a conventional Fab molecule.
[0192] In alternative embodiments, the antigen-binding domain(s) that bind to NKG2D are conventional Fab molecules. In such embodiments, the antigen-binding domain(s) that bind to a second antigen (e.g., a target cell antigen, e.g., a tumor cell antigen) are crossover Fab molecules as described herein, i.e., Fab molecules in which the variable domains VH and VL or the constant domains CH1 and CL of the Fab heavy and light chains have been swapped / replaced by one another.
[0193] In a preferred embodiment, the first antigen-binding domain is a Fab molecule in which the variable domains VL and VH or the constant domains CL and CH1 of the Fab light chain and the Fab heavy chain, in particular the variable domains VL and VH, are replaced by each other (i.e., according to such embodiment, the first antigen-binding domain is a crossover Fab molecule in which the variable or constant domains of the Fab light chain and the Fab heavy chain are exchanged). In one such embodiment, the second antigen-binding domain is a conventional Fab molecule.
[0194] b) a second antigen-binding domain In certain embodiments, the (multispecific) antibody of the invention comprises an antigen-binding domain (second antigen-binding domain) that binds to a second antigen. The second antigen is preferably not NKG2D, i.e., different from NKG2D. In one embodiment, the second antigen is an antigen expressed on cells different from NKG2D (e.g., expressed on cells other than T cells or NK cells). In one embodiment, the second antigen is not an activating Fc receptor, in particular FcγRIIIa (CD16a). In one embodiment, the antibody does not bind to an activating Fc receptor, in particular FcγRIIIa (CD16a). In one embodiment, the second antigen is not CD3. In one embodiment, the antibody does not bind to CD3.
[0195] In a preferred embodiment, the second antigen is a target cell antigen, in particular a tumor cell antigen. In a specific embodiment, the second antigen is CEA. According to the present invention, the second antigen-binding domain can direct the (multispecific) antibody to a target site, for example, to a specific type of tumor cell that expresses the second antigen.
[0196] In a preferred embodiment, the (multispecific) antibody comprises no more than one antigen-binding domain that binds to the second antigen. In one embodiment, the (multispecific) antibody provides monovalent binding to the second antigen. In another embodiment, the (multispecific) antibody comprises two or more (e.g., two, three, or four) antigen-binding domains that bind to the second antigen. In one embodiment, the (multispecific) antibody provides multivalent binding to the second antigen. In one embodiment, the (multispecific) antibody comprises two antigen-binding domains that bind to the second antigen. In one embodiment, the (multispecific) antibody provides bivalent binding to the second antigen.
[0197] In embodiments where a (multispecific) antibody comprises two or more antigen-binding domains, in particular Fab molecules, that bind to a second antigen, preferably each of these antigen-binding domains binds to the same antigenic determinant. In an even more preferred embodiment, all of these antigen-binding domains are identical, i.e., have the same molecular format (e.g., conventional or crossover Fab molecules) and comprise amino acid sequences that include the same amino acid substitutions in the CH1 and CL domains (if present) as described herein.
[0198] In one embodiment, the antigen-binding domain(s) that bind to the second antigen are antibody fragments selected from the group consisting of Fv molecules, scFv molecules, Fab molecules, and F(ab')2 molecules. In a preferred embodiment, the antigen-binding domain(s) that bind to the second antigen are Fab molecules. In another embodiment, the antigen-binding domain(s) that bind to the second antigen are Fv molecules.
[0199] In some embodiments, the antigen-binding domain(s) that bind to the second antigen are conventional Fab molecules. In such embodiments, the antigen-binding domain(s) that bind to NKG2D are crossover Fab molecules as described herein, i.e., Fab molecules in which the variable domains VH and VL or the constant domains CH1 and CL of the Fab heavy and light chains have been swapped / replaced by one another.
[0200] In alternative embodiments, the antigen-binding domain(s) that bind to the second antigen are crossover Fab molecules as described herein, i.e., Fab molecules in which the variable domains VH and VL or the constant domains CH1 and CL of the Fab heavy and light chains have been swapped / replaced. In such embodiments, the antigen-binding domain(s) that bind to NKG2D are conventional Fab molecules.
[0201] In one embodiment, the second antigen-binding domain comprises a human constant region. In one embodiment, the second antigen-binding domain is a Fab molecule comprising a human constant region, in particular a human CH1 and / or CL domain. Exemplary sequences of human constant domains are given in SEQ ID NOs: 83 and 84 (human kappa and lambda CL domains, respectively), and SEQ ID NO: 85 (human IgG1 heavy chain constant domain CH1-CH2-CH3). In one embodiment, the second antigen-binding domain comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO: 83 or SEQ ID NO: 84, in particular an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 83. In particular, the light chain constant region may comprise amino acid mutations as described herein in a "charge-modified" state and / or, in the case of a crossover Fab molecule, deletion or substitution of one or more (in particular two) N-terminal amino acids. In some embodiments, the second antigen-binding domain comprises a heavy chain constant region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the CH1 domain sequence contained in the amino acid sequence of SEQ ID NO: 85. In particular, the heavy chain constant region (specifically the CH1 domain) may comprise the amino acid mutations described herein in a "charge-modified" state.
[0202] In some embodiments, the second antigen is CEA, particularly human CEA.
[0203] In one aspect, the second antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1 of SEQ ID NO: 114, an HCDR2 of SEQ ID NO: 115 and an HCDR3 of SEQ ID NO: 116, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1 of SEQ ID NO: 117, an LCDR2 of SEQ ID NO: 118 and an LCDR3 of SEQ ID NO: 119.
[0204] In one aspect the second antigen binding domain comprises a VH comprising the heavy chain CDR sequences of the VH of SEQ ID NO: 120 and a VL comprising the light chain CDR sequences of the VL of SEQ ID NO: 121.
[0205] In one aspect, the VH of the second antigen-binding domain comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 120, and / or the VL of the second antigen-binding domain comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 121. In one aspect, the VH comprises the amino acid sequence of SEQ ID NO: 120 and / or the VL comprises the amino acid sequence of SEQ ID NO: 121.
[0206] In another aspect, the second antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 123, and an HCDR3 of SEQ ID NO: 124, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 127.
[0207] In one embodiment, the second antigen-binding domain is a humanized antibody (derived from a humanized antibody). In one embodiment, the second antigen-binding domain is a humanized antigen-binding domain (i.e., the antigen-binding domain of a humanized antibody). In one embodiment, the VH and / or VL of the second antigen-binding domain are humanized variable regions.
[0208] In one aspect, the VH of the second antigen-binding domain comprises an acceptor human framework, such as a human immunoglobulin framework or a human consensus framework.
[0209] In one aspect, the VH of the second antigen-binding domain comprises one or more heavy chain framework sequences (i.e., the FR1, FR2, FR3 and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO: 128. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence of SEQ ID NO: 128. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 128. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO: 128. In certain aspects, a VH sequence with at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, yet antibodies comprising that sequence retain the ability to bind to the second antigen. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 128. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VH comprises the amino acid sequence of SEQ ID NO: 128. Optionally, the VH comprises the amino acid sequence of SEQ ID NO: 128, including post-translational modifications of that sequence.
[0210] In one aspect, the VL of the second antigen-binding domain comprises one or more light chain framework sequences (i.e., the FR1, FR2, FR3 and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO: 129. In one aspect, the VL comprises an amino acid sequence at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence of SEQ ID NO: 129. In one aspect, the VL comprises an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 129. In one aspect, the VL comprises an amino acid sequence at least about 98% identical to the amino acid sequence of SEQ ID NO: 129. In certain aspects, a VL sequence with at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, yet antibodies comprising that sequence retain the ability to bind to the second antigen. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 129. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VL comprises the amino acid sequence of SEQ ID NO: 129. Optionally, the VL comprises the amino acid sequence of SEQ ID NO: 129, including post-translational modifications of that sequence.
[0211] In one aspect, the VH of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 128, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 129. In one aspect, the VH comprises the amino acid sequence of SEQ ID NO: 128 and the VL comprises the amino acid sequence of SEQ ID NO: 129.
[0212] In a further embodiment, the second antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 128 and a VL comprising the amino acid sequence of SEQ ID NO: 129.
[0213] In a further embodiment, the second antigen-binding domain comprises the VH sequence of SEQ ID NO: 128 and the VL sequence of SEQ ID NO: 129.
[0214] In another embodiment, the second antigen-binding domain comprises a VH comprising the heavy chain CDR sequences of the VH of SEQ ID NO: 128 and a VL comprising the light chain CDR sequences of the VL of SEQ ID NO: 129.
[0215] In a further aspect, the second antigen-binding domain comprises the VH HCDR1, HCDR2 and HCDR3 amino acid sequences of SEQ ID NO: 128 and the VL LCDR1, LCDR2 and LCDR3 amino acid sequences of SEQ ID NO: 129.
[0216] In one aspect, the VH of the second antigen-binding domain comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 128 and a framework of at least 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VH of SEQ ID NO: 128. In one aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 128 and a framework of at least 95% sequence identity to the framework sequence of the VH of SEQ ID NO: 128. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO: 128 and a framework of at least 98% sequence identity to the framework sequence of the VH of SEQ ID NO: 128.
[0217] In one aspect, the VL of the second antigen-binding domain comprises the light chain CDR sequence of the VL of SEQ ID NO: 129 and a framework of at least 95%, 96%, 97%, 98% or 99% sequence identity to the framework sequence of the VL of SEQ ID NO: 129. In one aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 129 and a framework of at least 95% sequence identity to the framework sequence of the VL of SEQ ID NO: 129. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 129 and a framework of at least 98% sequence identity to the framework sequence of the VL of SEQ ID NO: 129.
[0218] In another aspect, the second antigen-binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1 of SEQ ID NO: 165, an HCDR2 of SEQ ID NO: 168, and an HCDR3 of SEQ ID NO: 171, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1 of SEQ ID NO: 177, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 179. In one embodiment, the second antigen-binding domain comprises: (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 123, and an HCDR3 of SEQ ID NO: 172, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 180; (ii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 123, and an HCDR3 of SEQ ID NO: 173, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 181; (iii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 123, and an HCDR3 of SEQ ID NO: 174, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 182; (iv) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 166, an HCDR2 of SEQ ID NO: 169, and an HCDR3 of SEQ ID NO: 124, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 178, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 127; (v) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 170, and an HCDR3 of SEQ ID NO: 124, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 127; (vi) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 123, and an HCDR3 of SEQ ID NO: 175, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 183; (vii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 169, and an HCDR3 of SEQ ID NO: 175, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 183; (viii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 169, and an HCDR3 of SEQ ID NO: 175, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 183; (ix) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 123, and an HCDR3 of SEQ ID NO: 176, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 182; (x) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 122, an HCDR2 of SEQ ID NO: 169, and an HCDR3 of SEQ ID NO: 176, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 182; (xi) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 166, an HCDR2 of SEQ ID NO: 169, and an HCDR3 of SEQ ID NO: 172, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 180; or (xii) A heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 167, an HCDR2 of SEQ ID NO: 170, and an HCDR3 of SEQ ID NO: 172, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 125, an LCDR2 of SEQ ID NO: 126, and an LCDR3 of SEQ ID NO: 180.
[0219] In one embodiment, the second antigen-binding domain is a humanized antibody (derived from a humanized antibody). In one embodiment, the second antigen-binding domain is a humanized antigen-binding domain (i.e., the antigen-binding domain of a humanized antibody). In one embodiment, the VH and / or VL of the second antigen-binding domain are humanized variable regions.
[0220] In one aspect, the VH of the second antigen-binding domain comprises an acceptor human framework, such as a human immunoglobulin framework or a human consensus framework.
[0221] In one aspect, the VH of the second antigen-binding domain comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3 and / or FR4 sequences) of a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206. In one aspect, the VH comprises an amino acid sequence which is at least about 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206. In one aspect, the VH comprises an amino acid sequence at least about 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206. In one aspect, the VH comprises an amino acid sequence at least about 98% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206. In certain aspects, a VH sequence with at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, although an antibody comprising the sequence retains the ability to bind to a second antigen. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, or 206. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206. Optionally, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206, including post-translational modifications of that sequence.
[0222] In one aspect, the VL of the second antigen-binding domain comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3 and / or FR4 sequences) of a light chain variable region sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207. In one aspect, the VL comprises an amino acid sequence which is at least about 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to an amino acid sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, and 207. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to an amino acid sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, and 207. In certain aspects, a VL sequence with at least about 95%, about 96%, about 97%, about 98%, or about 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, although an antibody comprising the sequence retains the ability to bind to a second antigen. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, or 207. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In one embodiment, the VL comprises an amino acid sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, and 207. Optionally, the VL comprises an amino acid sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, and 207, including post-translational modifications of the sequence.
[0223] In one embodiment the VH of the second antigen-binding domain comprises (i) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 184, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 185; (ii) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 186, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 187; (iii) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 188, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 189; (iv) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 190, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 191; (v) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 192, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 193; (vi) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 194, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 195; (vii) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 196, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 197; (viii) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 198, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 199; (ix) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 200, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 201; (x) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 202, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 203; (xi) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 204, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 205; or (xii) comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 206, and the VL of the second antigen-binding domain comprises an amino acid sequence at least about 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 207.
[0224] In one aspect, the VH is (i) the VL comprises the amino acid sequence of SEQ ID NO: 184, and the VL comprises the amino acid sequence of SEQ ID NO: 185; (ii) comprises the amino acid sequence of SEQ ID NO: 186, and the VL comprises the amino acid sequence of SEQ ID NO: 187; (iii) comprises the amino acid sequence of SEQ ID NO: 188, and the VL comprises the amino acid sequence of SEQ ID NO: 189; (iv) comprises the amino acid sequence of SEQ ID NO: 190, and the VL comprises the amino acid sequence of SEQ ID NO: 191; (v) comprises the amino acid sequence of SEQ ID NO: 192, and the VL comprises the amino acid sequence of SEQ ID NO: 193; (vi) comprises the amino acid sequence of SEQ ID NO: 194, and the VL comprises the amino acid sequence of SEQ ID NO: 195; (vii) the VL comprises the amino acid sequence of SEQ ID NO: 197; (viii) comprises the amino acid sequence of SEQ ID NO: 198, and the VL comprises the amino acid sequence of SEQ ID NO: 199; (ix) comprises the amino acid sequence of SEQ ID NO: 200, and the VL comprises the amino acid sequence of SEQ ID NO: 201; (x) comprises the amino acid sequence of SEQ ID NO: 202, and the VL comprises the amino acid sequence of SEQ ID NO: 203; (xi) comprises the amino acid sequence of SEQ ID NO: 204, and the VL comprises the amino acid sequence of SEQ ID NO: 205; or (xii) comprises the amino acid sequence of SEQ ID NO: 206, and the VL comprises the amino acid sequence of SEQ ID NO: 207.
[0225] In a further aspect, the second antigen-binding domain comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 184 and a VL comprising the amino acid sequence of SEQ ID NO: 185; (ii) a VH comprising the amino acid sequence of SEQ ID NO: 186 and a VL comprising the amino acid sequence of SEQ ID NO: 187; (iii) a VH comprising the amino acid sequence of SEQ ID NO: 188 and a VL comprising the amino acid sequence of SEQ ID NO: 189; (iv) a VH comprising the amino acid sequence of SEQ ID NO: 190 and a VL comprising the amino acid sequence of SEQ ID NO: 191; (v) a VH comprising the amino acid sequence of SEQ ID NO: 192 and a VL comprising the amino acid sequence of SEQ ID NO: 193; (vi) a VH comprising the amino acid sequence of SEQ ID NO: 194 and a VL comprising the amino acid sequence of SEQ ID NO: 195; (vii) a VH comprising the amino acid sequence of SEQ ID NO: 196 and a VL comprising the amino acid sequence of SEQ ID NO: 197; (viii) a VH comprising the amino acid sequence of SEQ ID NO: 198 and a VL comprising the amino acid sequence of SEQ ID NO: 199; (ix) a VH comprising the amino acid sequence of SEQ ID NO: 200 and a VL comprising the amino acid sequence of SEQ ID NO: 201; (x) a VH comprising the amino acid sequence of SEQ ID NO: 202 and a VL comprising the amino acid sequence of SEQ ID NO: 203; (xi) a VH comprising the amino acid sequence of SEQ ID NO: 204 and a VL comprising the amino acid sequence of SEQ ID NO: 205; or (xii) VH comprising the amino acid sequence of SEQ ID NO: 206 and VL comprising the amino acid sequence of SEQ ID NO: 207.
[0226] In a further aspect, the second antigen-binding domain comprises: (i) a VH sequence of SEQ ID NO: 184 and a VL sequence of SEQ ID NO: 185; (ii) a VH sequence of SEQ ID NO: 186 and a VL sequence of SEQ ID NO: 187; (iii) a VH sequence of SEQ ID NO: 188 and a VL sequence of SEQ ID NO: 189; (iv) a VH sequence of SEQ ID NO: 190 and a VL sequence of SEQ ID NO: 191; (v) a VH sequence of SEQ ID NO: 192 and a VL sequence of SEQ ID NO: 193; (vi) a VH sequence of SEQ ID NO: 194 and a VL sequence of SEQ ID NO: 195; (vii) a VH sequence of SEQ ID NO: 196 and a VL sequence of SEQ ID NO: 197; (viii) a VH sequence of SEQ ID NO: 198 and a VL sequence of SEQ ID NO: 199; (ix) a VH sequence of SEQ ID NO: 200 and a VL sequence of SEQ ID NO: 201; (x) a VH sequence of SEQ ID NO: 202 and a VL sequence of SEQ ID NO: 203; (xi) a VH sequence of SEQ ID NO: 204 and a VL sequence of SEQ ID NO: 205; (xii) comprises the VH sequence of SEQ ID NO: 206 and the VL sequence of SEQ ID NO: 207.
[0227] In another embodiment, the second antigen-binding domain comprises: (i) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 184 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 185; (ii) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 186 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 187; (iii) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 188 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 189; (iv) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 190 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 191; (v) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 192 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 193; (vi) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 194 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 195; (vii) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 196 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 197; (viii) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 198 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 199; (ix) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 200 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 201; (x) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 202 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 203; (xi) a VH comprising the heavy chain CDR sequence of the VH of SEQ ID NO: 204 and a VL comprising the light chain CDR sequence of the VL of SEQ ID NO: 205; or (xii) A VH comprising the heavy chain CDR sequence of VH of SEQ ID NO: 206 and a VL comprising the light chain CDR sequence of VL of SEQ ID NO: 207.
[0228] In a further aspect, the second antigen-binding domain comprises: (i) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 184 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 185; (ii) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 186 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 187; (iii) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 188 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 189; (iv) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 190 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 191; (v) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 192 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 193; (vi) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 194 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 195; (vii) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 196 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 197; (viii) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 198 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 199; (ix) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 200 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 201; (x) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 202 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 203; (xi) the amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 204 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 205; or (xii) The amino acid sequences of HCDR1, HCDR2, and HCDR3 of VH of SEQ ID NO: 206 and the amino acid sequences of LCDR1, LCDR2, and LCDR3 of VL of SEQ ID NO: 207.
[0229] In one embodiment, the VH of the second antigen-binding domain comprises a VH heavy chain CDR sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206 and a framework sequence of at least 95%, 96%, 97%, 98% or 99% sequence identity to a VH framework sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206. In one aspect, the VH comprises a VH heavy chain CDR sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206 and a framework sequence of at least 95% sequence identity to a VH framework sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206. In another embodiment, the VH comprises a VH heavy chain CDR sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206, and a framework sequence of at least 98% sequence identity to a VH framework sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204 and 206.
[0230] In one embodiment, the VL of the second antigen-binding domain comprises a VL light chain CDR sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207 and a framework sequence of at least 95%, 96%, 97%, 98% or 99% sequence identity to a VL framework sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207. In one aspect, the VL comprises a VL light chain CDR sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207 and a framework sequence of at least 95% sequence identity to a VL framework sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207. In another embodiment, the VL comprises a VL light chain CDR sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207 and a framework sequence of at least 98% sequence identity to a VL framework sequence selected from the group of SEQ ID NOs: 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205 and 207.
[0231] In one aspect, the second antigen-binding domain comprises a VH sequence of any of the aspects provided in this section above and a VL sequence of any of the aspects provided in this section above.
[0232] c) Charge modification The (multispecific) antibodies of the present invention may contain amino acid substitutions in the Fab molecules contained therein that are particularly effective in reducing mispairing of light chains with incompatible heavy chains (Bence-Jones by-products) that can occur in the production of Fab-based multispecific antibodies with a VH / VL exchange in one (or more, in the case of molecules containing more than two antigen-binding Fab molecules) binding arm (see also WO 2015 / 150447, which is incorporated herein by reference in its entirety, in particular the Examples therein). The ratio of desired (multispecific) antibodies compared to undesired by-products, in particular Bence-Jones by-products that occur in multispecific antibodies with a VH / VL domain exchange in one of the binding arms, can be improved by introducing charged amino acids with an opposite charge to specific amino acid positions in the CH1 and CL domains (sometimes referred to herein as "charge modifications").
[0233] Thus, in some particular embodiments, where the first and second antigen-binding domains of the (multispecific) antibody are both Fab molecules, and in one of the antigen-binding domains (in particular the first antigen-binding domain), the variable domains VL and VH of the Fab light chain and the Fab heavy chain replace each other, i) in the constant domain CL of said second antigen-binding domain the amino acid at position 124 is substituted by a positively charged amino acid (Kabat numbering) and in the constant domain CH1 of said second antigen-binding domain the amino acid at position 147 or the amino acid at position 213 is substituted by a negatively charged amino acid (Kabat EU index numbering); or ii) in the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is substituted by a positively charged amino acid (Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 or the amino acid at position 213 is substituted by a negatively charged amino acid (Kabat EU index numbering).
[0234] A (multispecific) antibody does not contain both of the modifications described in i) and ii): the constant domains CL and CH1 of the antigen-binding domain with VH / VL exchange are not replaced by each other (i.e. remain unexchanged).
[0235] In a more specific aspect, i) in the constant domain CL of said second antigen-binding domain the amino acid at position 124 is substituted independently by lysine (K), arginine (R), or histidine (H) (Kabat numbering), and in the constant domain CH1 of said second antigen-binding domain the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering); or ii) in the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is independently substituted by lysine (K), arginine (R), or histidine (H) (Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 or the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0236] In one such embodiment, in the constant domain CL of the second antigen-binding domain the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (Kabat numbering), and in the constant domain CH1 of the second antigen-binding domain the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0237] In a further aspect, in the constant domain CL of said second antigen-binding domain, the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (Kabat numbering) and in the constant domain CH1 of said second antigen-binding domain, the amino acid at position 147 is substituted independently by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0238] In a preferred embodiment, in the constant domain CL of said second antigen-binding domain, the amino acid at position 124 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), and in the constant domain CHI of said second antigen-binding domain, the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0239] In a more preferred embodiment, in the constant domain CL of said second antigen-binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by lysine (K) (numbering according to Kabat); and in the constant domain CHI of said second antigen-binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to EU index of Kabat) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to EU index of Kabat).
[0240] In an even more preferred embodiment, in the constant domain CL of said second antigen-binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by arginine (R) (numbering according to Kabat); and in the constant domain CHI of said second antigen-binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to EU index of Kabat) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to EU index of Kabat).
[0241] In a preferred embodiment, when the amino acid substitutions according to the above embodiments are made in the constant domain CL and the constant domain CH1 of the second antigen-binding domain, the constant domain CL of the second antigen-binding domain is of the kappa isotype.
[0242] Alternatively, the amino acid substitutions according to the above embodiments are made in the constant domains CL and CH1 of the first antigen-binding domain instead of the constant domains CL and CH1 of the second antigen-binding domain. In a preferred such embodiment, the constant domain CL of the first antigen-binding domain is of the kappa isotype.
[0243] Thus, in one aspect, in the constant domain CL of the first antigen-binding domain the amino acid at position 124 is independently substituted by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat); and in the constant domain CH1 of the first antigen-binding domain the amino acid at position 147 or the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).
[0244] In a further aspect, in the constant domain CL of the first antigen-binding domain the amino acid at position 124 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering) and in the constant domain CH1 of the first antigen-binding domain the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0245] In yet another embodiment, in the constant domain CL of the first antigen-binding domain the amino acid at position 124 is independently substituted by lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted by lysine (K), arginine (R), or histidine (H) (Kabat numbering), and in the constant domain CHI of the first antigen-binding domain the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
[0246] In one embodiment, in the constant domain CL of said first antigen-binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by lysine (K) (numbering according to Kabat); and in the constant domain CHI of said first antigen-binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index).
[0247] In another embodiment, in the constant domain CL of said first antigen-binding domain the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by arginine (R) (numbering according to Kabat); and in the constant domain CHI of said first antigen-binding domain the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index).
[0248] In a preferred embodiment, the (multispecific) antibody of the invention comprises: (a) a first antigen-binding domain that binds to NKG2D, the first antigen-binding domain being a Fab molecule in which the Fab light chain and Fab heavy chain variable domains VL and VH are replaced with each other, and comprising a heavy chain variable region (VH) and a light chain variable region (VL) as in any of the embodiments provided herein for the first antigen-binding domain; (b) a second antigen-binding domain that binds to a second antigen, In the constant domain CL of the second (and, if present, the third) antigen-binding domain, the amino acid at position 124 is substituted independently by lysine (K), arginine (R), or histidine (H) (in a preferred embodiment, independently by lysine (K) or arginine (R)) (Kabat numbering), the amino acid at position 123 is substituted independently by lysine (K), arginine (R), or histidine (H) (in a preferred embodiment, independently by lysine (K) or arginine (R)) (Kabat numbering), and in the constant domain CHI of the second (and, if present, the third) antigen-binding domain, the amino acid at position 147 is substituted independently by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering). (EU index numbering), a second antigen-binding domain, and
[0249] d) Multispecific antibody formats The (multispecific) antibodies according to the invention can have a variety of structures, exemplary structures are depicted in Figure 12.
[0250] In a preferred embodiment, the antigen-binding domains comprised in the (multispecific) antibody are Fab molecules. In such embodiments, the first, second, etc. antigen-binding domains may be referred to herein as the first, second, etc. Fab molecules, respectively.
[0251] In preferred embodiments, the first and second antigen-binding domains are each Fab molecules. In some embodiments, the first and / or second (particularly the second) antigen-binding domain may be an Fv molecule.
[0252] In embodiments in which the first and second antigen-binding domains are each a Fab molecule, preferably the first antigen-binding domain is a crossover Fab molecule as described herein (i.e., a Fab molecule in which the Fab heavy and light chain variable domains VH and VL, or constant domains CH1 and CL, have been swapped / replaced each other) and the second antigen-binding domain is a conventional Fab molecule, or vice versa.
[0253] In embodiments in which the (multispecific) antibody comprises two or more antigen-binding domains that bind to NKG2D and / or two or more antigen-binding domains that bind to a second antigen, preferably all antigen-binding domains that bind to NKG2D are crossover Fab molecules as described herein and all antigen-binding domains that bind to the second antigen are conventional Fab molecules, or vice versa.
[0254] In a preferred embodiment, the (multispecific) antibody of the invention comprises an Fc domain composed of a first subunit and a second subunit, the first and second subunits of the Fc domain being capable of stable association.
[0255] The (multispecific) antibodies according to the invention can have different structures, i.e. the first, second and optionally further antigen-binding domains may be fused to each other and to the Fc domain in different ways. The components may be fused to each other directly or, preferably, via one or more suitable peptide linkers. When the fusion of a Fab molecule is to the N-terminus of a subunit of the Fc domain, it is typically via the immunoglobulin hinge region.
[0256] In a preferred embodiment, the (multispecific) antibody of the invention comprises: (a) a first antigen-binding domain that binds to NKG2D; (b) a second antigen-binding domain that binds to a second antigen; and (c) an Fc domain composed of a first subunit and a second subunit; and the first antigen-binding domain and the second antigen-binding domain are each a Fab molecule; (i) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, and a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, or (ii) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit.
[0257] An exemplary such configuration is shown in FIG. 12F.
[0258] In one such embodiment, the first antigen-binding domain is a crossover Fab molecule as described herein and the second antigen-binding domain is a conventional Fab molecule. In a more specific such embodiment, the first antigen-binding domain is a crossover Fab molecule in which the variable domains VH and VL have been swapped / replaced, and the second antigen-binding domain is a conventional Fab molecule comprising a charge modification as described herein.
[0259] In another such embodiment, the first antigen-binding domain is a conventional Fab molecule and the second antigen-binding domain is a crossover Fab molecule as described herein. In a more specific such embodiment, the first antigen-binding domain is a conventional Fab molecule comprising a charge modification as described herein and the second antigen-binding domain is a crossover Fab molecule in which the variable domains VH and VL have been swapped / replaced by one another.
[0260] In further such embodiments, the Fc domain comprises a modification that promotes association of a first subunit with a second subunit of the Fc domain, as described herein.
[0261] In still further such embodiments, the (multispecific) antibody consists essentially of a first and a second antigen-binding domain, an Fc domain and optionally one or more peptide linkers.
[0262] In another aspect, the bispecific antibody of the invention comprises: (a) a first antigen-binding domain that binds to NKG2D; (b) a second antigen-binding domain that binds to a second antigen; and (c) a third antigen-binding domain that binds to NKG2D; and (d) an Fc domain composed of a first subunit and a second subunit; the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain are each a Fab molecule; (i) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and a third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain; or (ii) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, and a third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain.
[0263] An exemplary such configuration is shown in FIG. 12E.
[0264] In one such embodiment, the first and third antigen-binding domains are each crossover Fab molecules as described herein and the second antigen-binding domain is a conventional Fab molecule. In a more specific such embodiment, the first and third antigen-binding domains are each crossover Fab molecules in which the variable domains VH and VL have been swapped / replaced, and the second antigen-binding domain is a conventional Fab molecule comprising charge modifications as described herein.
[0265] In another such embodiment, the first and third antigen-binding domains are each conventional Fab molecules and the second antigen-binding domain is a crossover Fab molecule as described herein. In more specific such embodiments, the first and third antigen-binding domains are each conventional Fab molecules comprising charge modifications as described herein and the second antigen-binding domain is a crossover Fab molecule in which the variable domains VH and VL have been swapped / replaced by one another.
[0266] In further such embodiments, the Fc domain comprises a modification that promotes association of a first subunit with a second subunit of the Fc domain, as described herein.
[0267] In still further such embodiments, the (multispecific) antibody consists essentially of a first, second and third antigen-binding domain, an Fc domain and optionally one or more peptide linkers.
[0268] In another aspect, the bispecific antibody of the invention comprises: (a) a first antigen-binding domain that binds to NKG2D; (b) a second antigen-binding domain that binds to a second antigen; and (c) a third antigen-binding domain that binds to NKG2D; and (d) an Fc domain composed of a first subunit and a second subunit; the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain are each a Fab molecule; (i) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, the second antigen-binding domain is fused at the N-terminus of the Fab heavy chain to the C-terminus of the second Fc domain subunit, and the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain; or (ii) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, the second antigen-binding domain is fused at the N-terminus of the Fab heavy chain to the C-terminus of the first Fc domain subunit, and the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain.
[0269] An exemplary such configuration is shown in FIG. 12C.
[0270] In one such embodiment, the first and third antigen-binding domains are each crossover Fab molecules as described herein and the second antigen-binding domain is a conventional Fab molecule. In a more specific such embodiment, the first and third antigen-binding domains are each crossover Fab molecules in which the variable domains VH and VL have been swapped / replaced, and the second antigen-binding domain is a conventional Fab molecule comprising charge modifications as described herein.
[0271] In another such embodiment, the first and third antigen-binding domains are each conventional Fab molecules and the second antigen-binding domain is a crossover Fab molecule as described herein. In more specific such embodiments, the first and third antigen-binding domains are each conventional Fab molecules comprising charge modifications as described herein and the second antigen-binding domain is a crossover Fab molecule in which the variable domains VH and VL have been swapped / replaced by one another.
[0272] In further such embodiments, the Fc domain comprises a modification that promotes association of a first subunit with a second subunit of the Fc domain, as described herein.
[0273] In still further such embodiments, the (multispecific) antibody consists essentially of a first, second and third antigen-binding domain, an Fc domain and optionally one or more peptide linkers.
[0274] In another aspect, the bispecific antibody of the invention comprises: (a) a first antigen-binding domain that binds to NKG2D; (b) a second antigen-binding domain that binds to a second antigen; and (c) a third antigen-binding domain that binds to NKG2D; and (d) a fourth antigen-binding domain that binds to NKG2D; and (e) a fifth antigen-binding domain that binds to NKG2D; and (f) an Fc domain composed of a first subunit and a second subunit; the first, second, third, fourth, and fifth antigen-binding domains are each a Fab molecule; (i) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the third antigen-binding domain, and the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit; (ii) the fourth antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the fifth antigen-binding domain, and the fifth antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit; and (iii) the second antigen-binding domain is fused at the N-terminus of the Fab heavy chain to the C-terminus of the first or second Fc domain subunit.
[0275] An exemplary such configuration is shown in FIG. 12B.
[0276] In one such embodiment, the first, third, fourth and fifth antigen-binding domains are each crossover Fab molecules as described herein and the second antigen-binding domain is a conventional Fab molecule. In a more specific such embodiment, the first, third, fourth and fifth antigen-binding domains are each crossover Fab molecules in which the variable domains VH and VL have been swapped / replaced with each other and the second antigen-binding domain is a conventional Fab molecule comprising charge modifications as described herein.
[0277] In another such embodiment, the first, third, fourth and fifth antigen-binding domains are each conventional Fab molecules and the second antigen-binding domain is a crossover Fab molecule as described herein. In a more specific such embodiment, the first, third, fourth and fifth antigen-binding domains are each conventional Fab molecules comprising charge modifications as described herein and the second antigen-binding domain is a crossover Fab molecule in which the variable domains VH and VL have been swapped / replaced by one another.
[0278] In further such embodiments, the Fc domain comprises a modification that promotes association of a first subunit with a second subunit of the Fc domain, as described herein.
[0279] In still further such embodiments, the (multispecific) antibody consists essentially of a first, second, third, fourth and fifth antigen-binding domain, an Fc domain and optionally one or more peptide linkers.
[0280] In another aspect, the bispecific antibody of the invention comprises: (a) a first antigen-binding domain that binds to NKG2D; (b) a second antigen-binding domain that binds to a second antigen; and (c) a third antigen-binding domain that binds to NKG2D; and (d) a fourth antigen-binding domain that binds to a second antigen; and (e) an Fc domain composed of a first subunit and a second subunit; the first, second, third, and fourth antigen-binding domains are each Fab molecules; The first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, the second antigen-binding domain is fused at the N-terminus of the Fab heavy chain to the C-terminus of the first Fc domain subunit, the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and the fourth antigen-binding domain is fused at the N-terminus of the Fab heavy chain to the C-terminus of the second Fc domain subunit.
[0281] An exemplary such configuration is shown in FIG. 12A.
[0282] In one such embodiment, the first and third antigen-binding domains are each crossover Fab molecules as described herein, and the second and fourth antigen-binding domains are each conventional Fab molecules. In a more specific such embodiment, the first and third antigen-binding domains are each crossover Fab molecules in which the variable domains VH and VL have been swapped / replaced, and the second and fourth antigen-binding domains are each conventional Fab molecules comprising charge modifications as described herein.
[0283] In another such embodiment, the first and third antigen-binding domains are each conventional Fab molecules, and the second and fourth antigen-binding domains are each crossover Fab molecules as described herein. In more specific such embodiments, the first and third antigen-binding domains are each conventional Fab molecules comprising charge modifications as described herein, and the second and fourth antigen-binding domains are each crossover Fab molecules in which the variable domains VH and VL have been swapped / replaced with each other.
[0284] In a further such embodiment, the (multispecific) antibody consists essentially of a first, second, third and fourth antigen-binding domain, an Fc domain and optionally one or more peptide linkers.
[0285] In another aspect, the bispecific antibody of the invention comprises: (a) a first antigen-binding domain that binds to NKG2D; (b) a second antigen-binding domain that binds to a second antigen; and (c) a third antigen-binding domain that binds to NKG2D; and (d) an Fc domain composed of a first subunit and a second subunit; the first antigen-binding domain and the third antigen-binding domain are each a Fab molecule, and the second antigen-binding domain is an Fv molecule; The first antigen-binding domain is fused to the N-terminus of the first Fc domain subunit at the C-terminus of the Fab heavy chain, the third antigen-binding domain is fused to the N-terminus of the second Fc domain subunit at the C-terminus of the Fab heavy chain, and the second antigen-binding domain is (i) fused to the C-terminus of the first Fc domain subunit at the N-terminus of the Fv heavy chain and fused to the C-terminus of the second Fc domain subunit at the N-terminus of the Fv light chain, or (ii) fused to the C-terminus of the second Fc domain subunit at the N-terminus of the Fv heavy chain and fused to the C-terminus of the first Fc domain subunit at the N-terminus of the Fv light chain.
[0286] An exemplary such configuration is shown in FIG. 12D.
[0287] In one such embodiment, the first antigen-binding domain and the third antigen-binding domain are each a conventional Fab molecule.
[0288] In further such embodiments, the Fc domain comprises a modification that promotes association of a first subunit with a second subunit of the Fc domain, as described herein.
[0289] In still further such embodiments, the (multispecific) antibody consists essentially of a first, second and third antigen-binding domain, an Fc domain and optionally one or more peptide linkers.
[0290] In the structure of a (multispecific) antibody in which the Fab molecules are fused via an immunoglobulin hinge region to the C-terminus of the Fab heavy chain and the N-terminus of each of the Fc domain subunits, the two Fab molecules, the hinge region, and the Fc domain essentially form an immunoglobulin molecule. In a preferred embodiment, the immunoglobulin molecule is an IgG class immunoglobulin. In an even more preferred embodiment, the immunoglobulin is an IgG1 subclass immunoglobulin. In another embodiment, the immunoglobulin is an IgG4 subclass immunoglobulin. In a further preferred embodiment, the immunoglobulin is a human immunoglobulin. In another embodiment, the immunoglobulin is a chimeric immunoglobulin or a humanized immunoglobulin. In one embodiment, the immunoglobulin comprises a human constant region, in particular a human Fc region.
[0291] The antigen-binding domains may be fused to the Fc domain or to each other directly or via a peptide linker comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art and are described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S) n , (SG4) n , (G4S) n or G4 (SG4) n Examples of suitable linkers include peptide linkers. "n" is generally an integer of 1 to 10, typically 2 to 4. In one embodiment, the peptide linker has a length of at least 5 amino acids, in another embodiment 5 to 100 amino acids, and in a further embodiment 10 to 50 amino acids. In one embodiment, the peptide linker has a length of (GxS) n or (GxS) n G mwherein G=glycine, S=serine and (x=3, n=3, 4, 5 or 6, m=0, 1, 2 or 3) or (x=4, n=2, 3, 4 or 5, m=0, 1, 2 or 3), and in one embodiment x=4 and n=2 or 4. In one embodiment the peptide linker is (G4S)2 or (G4S)4. In a particular embodiment, the peptide linker for fusing the Fab heavy chains of the first and second Fab molecules to each other in the multispecific antibody format described above is (G4S)2. In a further particular embodiment, the peptide linker for fusing a Fab molecule or Fv molecule to the C-terminus of the Fc domain in the multispecific antibody format described herein above is (G4S)4. Suitable peptide linkers may also comprise (part of) an immunoglobulin hinge region. In particular, when a Fab molecule is fused to the N-terminus of an Fc domain subunit, it may be fused via an immunoglobulin hinge region or part thereof, with or without an additional peptide linker. In a particular embodiment, the fusion of a Fab molecule to the N-terminus of an Fc domain subunit in the multispecific antibody formats described hereinabove is via an immunoglobulin hinge region, preferably an immunoglobulin hinge region of the same subclass as the Fc domain (e.g., an IgG1 hinge region where the Fc domain is of the IgG1 subclass).
[0292] In one aspect, the present invention provides a method for producing a pharmaceutical composition comprising: (a) a first antigen-binding domain that binds to NKG2D, the first antigen-binding domain comprising a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR)1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 104, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR)1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78; (b) a second antigen-binding domain that binds to a second antigen, particularly a target cell antigen, more particularly a tumor cell antigen; and (c) an Fc domain composed of a first subunit and a second subunit; and the first antigen-binding domain and the second antigen-binding domain are each a Fab molecule; (i) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, and a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, or (ii) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit.
[0293] In one aspect, the present invention provides a method for producing a pharmaceutical composition comprising: (a) a first antigen-binding domain that binds to NKG2D, the first antigen-binding domain comprising a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR)1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 104, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR)1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78; (b) a second antigen-binding domain that binds to a second antigen, particularly a target cell antigen, more particularly a tumor cell antigen; and (c) an Fc domain composed of a first subunit and a second subunit, the Fc domain comprising a modification that promotes association of the first subunit with the second subunit of the Fc domain; the first antigen-binding domain and the second antigen-binding domain are each a Fab molecule; (i) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, and a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, or (ii) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit.
[0294] In one aspect, the present invention provides a method for producing a pharmaceutical composition comprising: (a) a first antigen-binding domain that binds to NKG2D, the first antigen-binding domain comprising a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR)1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 104, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR)1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78; (b) a second antigen-binding domain that binds to a second antigen, particularly a target cell antigen, more particularly a tumor cell antigen; and (c) an Fc domain composed of a first subunit and a second subunit, the first antigen-binding domain and the second antigen-binding domain are each a Fab molecule; (i) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, and a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, or (ii) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, Provided are (multispecific) antibodies, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function, and / or wherein the antibody does not bind to FcγRIIIa (CD16a).
[0295] In one aspect, the present invention provides a method for producing a pharmaceutical composition comprising: a) a first antigen-binding domain that binds to NKG2D, the first antigen-binding domain being a Fab molecule in which the variable domains VL and VH of the Fab light chain and the constant domains CL and CH1 of the Fab heavy chain are replaced with each other, the first antigen-binding domain comprising a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 104, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78; b) a second antigen-binding domain that binds to a second antigen, in particular a target cell antigen, more particularly a tumor cell antigen, wherein the second antigen-binding domain is a (traditional) Fab molecule; c) an Fc domain composed of a first subunit and a second subunit, (i) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, and a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, or (ii) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit.
[0296] In all the different structures of the (multispecific) antibodies according to the invention, the amino acid substitutions ("charge modifications") described herein, if present, may be in either the CH1 and CL domains of the second antigen-binding domain / Fab molecule or the CH1 or CL domain of the first antigen-binding domain / Fab molecule. Preferably, they are located in the CH1 and CL domains of the second antigen-binding domain / Fab molecule. In accordance with the inventive concept, when an amino acid substitution described herein is made in the second antigen-binding domain / Fab molecule, such an amino acid substitution is not made in the first antigen-binding domain / Fab molecule. Conversely, when an amino acid substitution described herein is made in the first antigen-binding domain / Fab molecule, such an amino acid substitution is not made in the second antigen-binding domain / Fab molecule. The amino acid substitutions are preferably made in (multispecific) antibodies comprising Fab molecules in which the variable domains VL and VH1 of the Fab light chain and the Fab heavy chain are replaced by each other.
[0297] In preferred embodiments of the (multispecific) antibodies according to the invention, particularly when the amino acid substitutions described herein are made in the second antigen-binding domain / Fab molecule, the constant domain CL of the second Fab molecule is of the kappa isotype. In other embodiments of the (multispecific) antibodies according to the invention, particularly when the amino acid substitutions described herein are made in the first antigen-binding domain / Fab molecule, the constant domain CL of the first antigen-binding domain / Fab molecule is of the kappa isotype. In some embodiments, the constant domain CL of the second antigen-binding domain / Fab molecule as well as the constant domain CL of the first antigen-binding domain / Fab molecule are of the kappa isotype.
[0298] In one aspect, the present invention provides a method for producing a pharmaceutical composition comprising: a) a first antigen-binding domain that binds to NKG2D, the first antigen-binding domain being a Fab molecule in which the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced with each other, the first antigen-binding domain comprising a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO: 73, an HCDR2 of SEQ ID NO: 104, and an HCDR3 of SEQ ID NO: 75, and a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR) 1 of SEQ ID NO: 76, an LCDR2 of SEQ ID NO: 77, and an LCDR3 of SEQ ID NO: 78; b) a second antigen-binding domain that binds to a second antigen, in particular a target cell antigen, more particularly a tumor cell antigen, wherein the second antigen-binding domain is a (traditional) Fab molecule; c) an Fc domain composed of a first subunit and a second subunit, in the constant domain CL of the second antigen-binding domain of b) the amino acid at position 124 is substituted by lysine (K) (numbering according to Kabat) and the amino acid at position 123 is substituted by lysine (K) or arginine (R), most preferably by arginine (R) (numbering according to Kabat); and in the constant domain CHI of the second antigen-binding domain of b) the amino acid at position 147 is substituted by glutamic acid (E) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted by glutamic acid (E) (numbering according to Kabat EU index); (i) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit, and a second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, or (ii) a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second Fc domain subunit, and a first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first Fc domain subunit.
[0299] According to any of the above embodiments, the components of the (multispecific) antibody (e.g., Fab molecules, Fc domains) may be fused directly or via various linkers, in particular via peptide linkers comprising one or more amino acids, typically about 2 to 20 amino acids, as described herein or known in the art. Suitable non-immunogenic peptide linkers include, for example, (G4S) n , (SG4) n , (G4S) n or G4 (SG4) n A peptide linker is included, and "n" is usually an integer from 1 to 10, typically from 2 to 4.
[0300] In one embodiment according to these aspects of the invention, the first antigen-binding domain comprises a VH comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 112, and / or a VL comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 80.
[0301] In one embodiment according to these aspects of the invention, in the first subunit of the Fc domain, the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the second subunit of the Fc domain, the tyrosine residue at position 407 is replaced with a valine residue (Y407V), and optionally the threonine residue at position 366 is replaced with a serine residue (T366S), and the leucine residue at position 368 is replaced with an alanine residue (L368A) (numbering according to the Kabat EU index).
[0302] In a further embodiment according to these aspects of the invention, the first subunit of the Fc domain additionally has a replacement of the serine residue at position 354 with a cysteine residue (S354C) or a replacement of the glutamic acid residue at position 356 with a cysteine residue (E356C) (particularly, the replacement of the serine residue at position 354 with a cysteine residue), and the second subunit of the Fc domain additionally has a replacement of the tyrosine residue at position 349 with a cysteine residue (Y349C) (numbering according to the Kabat EU index).
[0303] In a further embodiment according to these aspects of the invention, in each of the first and second subunits of the Fc domain, the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced with a glycine residue (P329G) (numbering according to the Kabat EU index).
[0304] In a further embodiment according to these aspects of the invention, the Fc domain is a human IgG1 Fc domain.
[0305] In one aspect, the invention provides (multispecific) antibodies that bind to NKG2D and CEA, comprising a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 209, a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 210, a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 211, and a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 212. In one aspect, the invention provides (multispecific) antibodies that bind to NKG2D and CEA, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 209, a polypeptide comprising the amino acid sequence of SEQ ID NO: 210, a polypeptide comprising the amino acid sequence of SEQ ID NO: 211, and a polypeptide comprising the amino acid sequence of SEQ ID NO: 212.
[0306] In another aspect, the present invention provides (multispecific) antibodies that bind to NKG2D and CEA, comprising a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 213, a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 214, a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 215, and a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 216. In one aspect, the present invention provides (multispecific) antibodies that bind to NKG2D and CEA, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 213, a polypeptide comprising the amino acid sequence of SEQ ID NO: 214, a polypeptide comprising the amino acid sequence of SEQ ID NO: 215, and a polypeptide comprising the amino acid sequence of SEQ ID NO: 216.
[0307] In a further aspect, the invention relates to a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 213, and a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 214, wherein the VL region sequence (SEQ ID NO: 193) is replaced by a VL region sequence selected from the group consisting of SEQ ID NOs: 185, 187, 189, 191, 195, 197, 199, 201, 203, 205 and 207. and a polypeptide comprising an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 216, wherein the VH region sequence (SEQ ID NO: 192) is replaced by a VH region sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 194, 196, 198, 200, 202, 204 and 206.
[0023] In one aspect, the invention provides a (multispecific) antibody that binds to NKG2D and CEA, comprising: a polypeptide comprising the amino acid sequence of SEQ ID NO: 213; a polypeptide comprising the amino acid sequence of SEQ ID NO: 214 in which the VL-region sequence (SEQ ID NO: 193) is replaced by a VL-region sequence selected from the group consisting of SEQ ID NOs: 185, 187, 189, 191, 195, 197, 199, 201, 203, 205 and 207; a polypeptide comprising the amino acid sequence of SEQ ID NO: 215; and a polypeptide comprising the amino acid sequence of SEQ ID NO: 216 in which the VH-region sequence (SEQ ID NO: 192) is replaced by a VH-region sequence selected from the group consisting of SEQ ID NOs: 184, 186, 188, 190, 194, 196, 198, 200, 202, 204 and 206. Preferably, in the above embodiments, the VH and VL regions (SEQ ID NOs: 192 and 193) are replaced by a pair of VH and VL regions corresponding to a binding agent identified in Table 16.
[0308] 2. Fc domain mutants In a preferred embodiment, the (multispecific) antibody of the invention comprises an Fc domain composed of a first subunit and a second subunit.
[0309] The Fc domain of a (multispecific) antibody consists of a pair of polypeptide chains comprising the heavy chain domains of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, with each subunit comprising the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain are capable of stable association with each other. In one embodiment, the (multispecific) antibody of the present invention does not comprise more than one Fc domain.
[0310] In one embodiment, the Fc domain of the (multispecific) antibody is an IgG Fc domain. In a preferred embodiment, the Fc domain is an IgG1 Fc domain. In another embodiment, the Fc domain is an IgG4 Fc domain. In a more specific embodiment, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position S228, in particular the amino acid substitution S228P (Kabat EU index numbering). This amino acid substitution reduces Fab arm exchange of IgG4 antibodies in vivo (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In a further preferred embodiment, the Fc domain is a human Fc domain. In a more preferred embodiment, the Fc domain is a human IgG1 Fc domain. An exemplary sequence of a human IgG1 Fc region is given in SEQ ID NO: 86.
[0311] a) Fc domain modifications that promote heterodimerization The (multispecific) antibodies according to the invention comprise different antigen-binding domains which may be fused to one or the other of the two subunits of the Fc domain, which are therefore typically comprised in two non-identical polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization results in several possible combinations of the two polypeptides. To improve the yield and purity of (multispecific) antibodies in recombinant production, it is advantageous to introduce modifications in the Fc domain of the (multispecific) antibody that facilitate the association of the desired polypeptides.
[0312] Thus, in a preferred embodiment, the Fc domain of a (multispecific) antibody according to the invention comprises a modification that promotes the association of the first and second subunits of the Fc domain. The longest site of protein-protein interaction between the two subunits of a human IgG Fc domain is within the CH3 domain of the Fc domain. Thus, in one embodiment, the modification is in the CH3 domain of the Fc domain.
[0313] There are several approaches to modifications in the CH3 domain of an Fc domain to enhance heterodimerization, which are fully described in, for example, WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012058768, WO 2013157954, WO 2013096291. Typically, in all such approaches, the CH3 domains of the first Fc subunit and the second Fc subunit are engineered in a complementary manner such that each CH3 domain (or the heavy chain containing it) can no longer homodimerize with itself but heterodimerize with another complementary engineered CH3 domain (i.e., the first and second CH3 domains heterodimerize and homodimerization between the two first or two second CH3 domains is not possible). These different approaches to improved heavy chain heterodimerization are considered as different alternatives in combination with heavy-light chain modifications in (multispecific) antibodies to reduce heavy / light chain mispairing and Bence-Jones side products (e.g., swapping / replacing VH and VL in one binding arm and introducing oppositely charged amino acid substitutions at the CH1 / CL interface).
[0314] In a specific embodiment, the modification that promotes association of the first and second subunits of the Fc domain is a so-called "knob-into-hole" modification, which comprises a "knob" modification on one of the two subunits of the Fc domain and a "hole" modification on the other of the two subunits of the Fc domain.
[0315] Knob-into-hole technology is described, for example, in U.S. Pat. No. 5,731,168, U.S. Pat. No. 7,695,936, Ridgway et al., Prot Eng 9, 617-621 (1996), and Carter, J Immunol Meth 248, 7-15 (2001). Generally, this method involves introducing a protrusion ("knob") at the interface of a first polypeptide and a cavity ("hole") at the interface of a second polypeptide, such that the protrusion can be positioned within the cavity to promote heterodimer formation and prevent homodimer formation. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A complementary cavity of identical or similar size to the protrusion is created at the interface of the second polypeptide by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine).
[0316] Thus, in a preferred embodiment, in the CH3 domain of a first subunit of the Fc domain of a (multispecific) antibody, amino acid residues are replaced with amino acid residues having a larger side chain mass, thereby generating a protrusion in the CH3 domain of the first subunit that can be positioned in a cavity in the CH3 domain of a second subunit, and in the CH3 domain of a second subunit of the Fc domain, amino acid residues are replaced with amino acid residues having a smaller side chain mass, thereby generating a cavity in the CH3 domain of the second subunit into which the protrusion in the CH3 domain of the first subunit can be positioned.
[0317] Preferably, the amino acid residue with the larger side chain mass is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W).
[0318] Preferably, the amino acid residue with the smaller side chain mass is selected from the group consisting of alanine (A), serine (S), threonine (T) and valine (V).
[0319] The protrusions and cavities can be created by altering the nucleic acid encoding the polypeptide, for example, by site-directed mutagenesis or by peptide synthesis.
[0320] In a specific embodiment, in the (CH3 domain of) the first subunit ("knob" subunit) of the Fc domain, the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the (CH3 domain of) the second subunit ("hole" subunit) of the Fc domain, the tyrosine residue at position 407 is replaced with a valine residue (Y407V). In one embodiment, in the second subunit of the Fc domain, additionally, the threonine residue at position 366 is replaced with a serine residue (T366S), and the leucine residue at position 368 is replaced with an alanine residue (L368A) (numbering according to the Kabat EU index).
[0321] In a further embodiment, the first subunit of the Fc domain additionally replaces the serine residue at position 354 with a cysteine residue (S354C) or the glutamic acid residue at position 356 with a cysteine residue (E356C) (particularly, the serine residue at position 354 is replaced with a cysteine residue), and the second subunit of the Fc domain additionally replaces the tyrosine residue at position 349 with a cysteine residue (Y349C) (numbering according to the Kabat EU index). The introduction of these two cysteine residues results in the formation of disulfide bridges between the two subunits of the Fc domain, further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).
[0322] In a preferred embodiment, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A and Y407V (numbering according to the Kabat EU index).
[0323] In a preferred embodiment, an antigen-binding domain that binds CD3 is fused (optionally via a second antigen-binding domain that binds a second antigen and / or a peptide linker) to a first subunit of an Fc domain (comprising the "knob" modification). Without being bound by theory, fusing an antigen-binding domain that binds CD3 to a knob-containing subunit of an Fc domain (further) minimizes the generation of antibodies comprising two antigen-binding domains that bind CD3 (steric clash of the two knob-containing polypeptides).
[0324] Other techniques for CH3 modifications that enhance heterodimerization are contemplated as alternatives in accordance with the present invention and are described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, and WO 2013 / 096291.
[0325] In one embodiment, the heterodimerization technique described in EP 1 870 459 is used instead. This technique is based on the introduction of oppositely charged amino acids at specific amino acid positions in the CH3 / CH3 domain interface between the two subunits of the Fc domain. A particular embodiment of the (multispecific) antibody of the invention comprises the amino acid mutations R409D, K370E in one of the two CH3 domains (of the Fc domain) and D399K, E357K in the other CH3 domain of the Fc domain (numbering according to the Kabat EU index).
[0326] In another embodiment, the (multispecific) antibody of the invention comprises the amino acid mutation T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations T366S, L368A, Y407V in the CH3 domain of the second subunit of the Fc domain, and additionally the amino acid mutations R409D, K370E in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations D399K, E357K in the CH3 domain of the second subunit of the Fc domain (numbering according to Kabat EU index).
[0327] In another embodiment, the (multispecific) antibody of the invention comprises the amino acid mutations S354C, T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations Y349C, T366S, L368A, Y407V in the CH3 domain of the second subunit of the Fc domain, or said (multispecific) antibody comprises the amino acid mutations Y349C, T366W in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations S354C, T366S, L368A, Y407V in the CH3 domain of the second subunit of the Fc domain, and additionally the amino acid mutations R409D, K370E in the CH3 domain of the first subunit of the Fc domain and the amino acid mutations D399K, E357K in the CH3 domain of the second subunit of the Fc domain (all numbering according to Kabat EU index).
[0328] In one embodiment, the heterodimerization technique described in WO 2013 / 157953 is used instead. In one embodiment, the first CH3 domain comprises the amino acid mutation T366K and the second CH3 domain comprises the amino acid mutation L351D (numbering according to the Kabat EU index). In a further embodiment, the first CH3 domain comprises the additional amino acid mutation L351K. In a further embodiment, the second CH3 domain further comprises an amino acid mutation selected from Y349E, Y349D, and L368E (particularly L368E) (numbering according to the Kabat EU index).
[0329] In one embodiment, the heterodimerization approach described in WO 2012 / 058768 is alternatively used. In one embodiment, the first CH3 domain comprises the amino acid mutations L351Y and Y407A, and the second CH3 domain comprises the amino acid mutations T366A and K409F. In a further embodiment, the second CH3 domain comprises the amino acid mutations T411, D399, S400, F405, N390, or K392, for example: a) T411N, T411R, T411Q, T411K, T411D, T411E, or T411W; b) D399R, D399W, D399Y, or D399K; c) S400E, S409F, or S411N, T411R, T411Q, T411K, T411D, T411E, or T411W; In a further aspect, the first CH3 domain comprises an amino acid mutation selected from: d) F405I, F405M, F405T, F405S, F405V or F405W; e) N390R, N390K or N390D; f) K392V, K392M, K392R, K392L, K392F or K392E (numbering according to the Kabat EU index). In a further aspect, the first CH3 domain comprises the amino acid mutations L351Y, Y407A and the second CH3 domain comprises the amino acid mutations T366V, K409F. In a further aspect, the first CH3 domain comprises the amino acid mutation Y407A and the second CH3 domain comprises the amino acid mutations T366A, K409F. In a further embodiment, the second CH3 domain further comprises the amino acid mutations K392E, T411E, D399R and S400R (numbering according to the Kabat EU index).
[0330] In one aspect, the heterodimerization approach described in WO 2011 / 143545 is alternatively used, e.g., with an amino acid modification at position selected from the group consisting of 368 and 409 (numbering according to the Kabat EU index).
[0331] In one embodiment, the heterodimerization approach described in WO 2011 / 090762, which also employs the knob-into-hole technique described above, is alternatively used. In one embodiment, the first CH3 domain comprises the amino acid mutation T366W and the second CH3 domain comprises the amino acid mutation Y407A. In one embodiment, the first CH3 domain comprises the amino acid mutation T366Y and the second CH3 domain comprises the amino acid mutation Y407T (numbering according to the Kabat EU index).
[0332] In one embodiment, the (multispecific) antibody or Fc domain thereof is of the IgG2 subclass and the heterodimerization approach described in WO 2010 / 129304 is alternatively used.
[0333] In an alternative embodiment, the modification that promotes association between the first and second subunits of the Fc domain comprises a modification that mediates electrostatic steering effects, e.g., as described in PCT Application WO 2009 / 089004. Generally, this method involves replacing one or more amino acid residues at the interface of the two Fc domain subunits with charged amino acid residues such that homodimer formation is electrostatically unfavorable, but heterodimerization is electrostatically favorable. In one such embodiment, the first CH3 domain comprises an amino acid substitution of K392 or N392 with a negatively charged amino acid (e.g., with glutamic acid (E) or aspartic acid (D), particularly K392D or N392D), and the second CH3 domain comprises an amino acid substitution of D399, E356, D356, or E357 with a positively charged amino acid (e.g., with lysine (K) or arginine (R), particularly D399K, E356K, D356K, or E357K, more particularly D399K and E356K). In a further embodiment, the first CH3 domain further comprises an amino acid substitution of K409 or R409 with a negatively charged amino acid (e.g., with glutamic acid (E) or aspartic acid (D), particularly K409D or R409D). In a further aspect, the first CH3 domain additionally or alternatively comprises an amino acid substitution at K439 and / or K370 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D)) (all numbering according to the Kabat EU index).
[0334] In a further aspect, the heterodimerization approach described in WO 2007 / 147901 is alternatively used. In one aspect, the first CH3 domain comprises the amino acid mutations K253E, D282K, and K322D, and the second CH3 domain comprises the amino acid mutations D239K, E240K, and K292D (numbering according to the Kabat EU index).
[0335] In yet another embodiment, the heterodimerization approach described in WO 2007 / 110205 can alternatively be used.
[0336] In one aspect, the first subunit of the Fc domain comprises the amino acid substitutions K392D and K409D, and the second subunit of the Fc domain comprises the amino acid substitutions D356K and D399K (numbering according to the Kabat EU index).
[0337] b) Fc domain modifications that reduce Fc receptor binding and / or effector function The Fc domain confers favorable pharmacokinetic properties and favorable tissue-blood distribution ratios to (multispecific) antibodies, including a long serum half-life that contributes to favorable accumulation in target tissues. At the same time, Fc domain-mediated binding of (multispecific) antibodies to cells expressing Fc receptors can lead to cross-linking of Fc receptor-expressing cells (e.g., NK cells) with other NKG2D-expressing cells (e.g., CD8 T cells), potentially resulting in undesirable toxicity upon systemic administration. Furthermore, simultaneous activation of Fc receptor signaling pathways can result in cytokine release, which, combined with the T cell-activating properties and long half-life of (multispecific) antibodies, can result in excessive cytokine receptor activation and severe side effects upon systemic administration. Activation of (Fc receptor-bearing) immune cells other than T cells can even reduce the efficacy of (multispecific) antibodies, for example, due to the potential for T cell destruction by NK cells.
[0338] Thus, in a preferred embodiment, the Fc domain of a (multispecific) antibody according to the invention exhibits reduced binding affinity to an Fc receptor and / or reduced effector function compared to a native IgG1 Fc domain. In one such embodiment, the Fc domain (or a (multispecific) antibody comprising said Fc domain) exhibits less than 50%, particularly less than 20%, more particularly less than 10%, and most particularly less than 5% of the binding affinity to an Fc receptor compared to a native IgG1 Fc domain (or a (multispecific) antibody comprising a native IgG1 Fc domain), and / or exhibits less than 50%, particularly less than 20%, more particularly less than 10%, and most particularly less than 5% of the effector function compared to a native IgG1 Fc domain (or a (multispecific) antibody comprising a native IgG1 Fc domain). In one embodiment, the Fc domain (or a (multispecific) antibody comprising said Fc domain) does not substantially bind to an Fc receptor and / or does not induce effector function. In a preferred embodiment, the Fc receptor is an Fcγ receptor. In one embodiment, the Fc receptor is a human Fc receptor. In one embodiment, the Fc receptor is an activating Fc receptor. In a specific embodiment, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI, or FcγRIIa, and most specifically human FcγRIIIa (CD16a). In one embodiment, the effector function is one or more selected from the group consisting of CDC, ADCC, ADCP, and cytokine secretion. In a preferred embodiment, the effector function is ADCC. In one embodiment, the Fc domain exhibits substantially similar binding affinity to the neonatal Fc receptor (FcRn) compared to a native IgG1 Fc domain. Substantially similar binding to FcRn is achieved when the Fc domain (or a (multispecific) antibody comprising said Fc domain) exhibits more than about 70%, particularly more than about 80%, and more particularly more than about 90% of the binding affinity for FcRn of a native IgG1 Fc domain (or a (multispecific) antibody comprising a native IgG1 Fc domain).
[0339] In certain embodiments, the Fc domain is engineered to have reduced binding affinity to an Fc receptor and / or reduced effector function compared to a non-engineered Fc domain. In preferred embodiments, the Fc domain of a (multispecific) antibody comprises one or more amino acid mutations that reduce the binding affinity of the Fc domain to an Fc receptor and / or the effector function. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In one embodiment, the amino acid mutations reduce the binding affinity of the Fc domain to an Fc receptor. In one embodiment, the amino acid mutations reduce the binding affinity of the Fc domain to an Fc receptor by at least 2-fold, at least 5-fold, or at least 10-fold. In embodiments where more than one amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor is present, the combination of these amino acid mutations may reduce the binding affinity of the Fc domain to an Fc receptor by at least 10-fold, at least 20-fold, or even at least 50-fold. In one embodiment, a (multispecific) antibody comprising an engineered Fc domain exhibits less than 20%, particularly less than 10%, and more particularly less than 5% of the binding affinity to an Fc receptor compared to a (multispecific) antibody comprising a non-engineered Fc domain. In a preferred embodiment, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fc receptor. In some embodiments, the Fc receptor is an activating Fc receptor. In a specific embodiment, the Fc receptor is an activating human Fcγ receptor, more particularly human FcγRIIIa, FcγRI, or FcγRIIa, and most particularly human FcγRIIIa (CD16a). Preferably, binding to these respective receptors is reduced. In some embodiments, binding affinity to complement components (particularly binding affinity to C1q) is also reduced. In one embodiment, binding affinity to neonatal Fc receptor (FcRn) is not reduced. Substantially similar binding to FcRn, i.e., preservation of the binding affinity of the Fc domain to the receptor, is achieved when the Fc domain (or a (multispecific) antibody comprising the Fc domain) exhibits greater than about 70% of the binding affinity for FcRn of the non-engineered form of the Fc domain (or a (multispecific) antibody comprising the non-engineered form of the Fc domain).The Fc domain or a (multispecific) antibody of the invention comprising said Fc domain may exhibit more than about 80%, or even more than about 90%, of such affinity. In certain embodiments, the Fc domain of the (multispecific) antibody is engineered to have reduced effector function compared to a non-engineered Fc domain. Reduced effector function may include, but is not limited to, one or more of: reduced complement-dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling-induced apoptosis, reduced cross-linking of target-bound antibodies, reduced dendritic cell maturation, or reduced T cell priming. In one embodiment, the reduced effector function is one or more selected from the group consisting of reduced CDC, reduced ADCC, reduced ADCP, and reduced cytokine secretion. In a preferred embodiment, the reduced effector function is reduced ADCC. In one embodiment, the reduction in ADCC is less than 20% of the ADCC induced by a non-engineered Fc domain (or a (multispecific) antibody comprising a non-engineered Fc domain).
[0340] In one aspect, the amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor and / or the effector function is an amino acid substitution. In one aspect, the Fc domain comprises an amino acid substitution at a position selected from the group of E233, L234, L235, N297, P331, and P329 (numbering according to Kabat EU index). In a more specific aspect, the Fc domain comprises an amino acid substitution at a position selected from the group of L234, L235, and P329 (numbering according to Kabat EU index). In some aspects, the Fc domain comprises amino acid substitutions L234A and L235A (numbering according to Kabat EU index). In one such aspect, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. In one aspect, the Fc domain comprises an amino acid substitution at position P329. In a more specific embodiment, the amino acid substitution is P329A or P329G, particularly P329G (numbering according to Kabat EU index). In one embodiment, the Fc domain comprises an amino acid substitution at position P329 and a further amino acid substitution at a position selected from E233, L234, L235, N297 and P331 (numbering according to Kabat EU index). In a more specific embodiment, the further amino acid substitution is E233P, L234A, L235A, L235E, N297A, N297D or P331S. In a preferred embodiment, the Fc domain comprises amino acid substitutions at positions P329, L234 and L235 (numbering according to Kabat EU index). In a more preferred embodiment, the Fc domain comprises the amino acid mutations L234A, L235A and P329G (“P329G LALA”, “PGLALA” or “LALAPG”).Specifically, in a preferred embodiment, each subunit of the Fc domain contains the amino acid substitutions L234A, L235A, and P329G (Kabat EU index numbering), i.e., in each of the first and second subunits of the Fc domain, the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced with a glycine residue (P329G) (Kabat EU index numbering).
[0341] In one such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. The "P329G LALA" combination of amino acid substitutions almost completely abolishes Fcγ receptor (as well as complement) binding of the human IgG1 Fc domain, as described in WO 2012 / 130831, the entire contents of which are incorporated herein by reference. WO 2012 / 130831 also describes methods for preparing such mutant Fc domains and determining their properties, such as Fc receptor binding or effector function.
[0342] IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector function compared to IgG1 antibodies. Thus, in some embodiments, the Fc domain of the (multispecific) antibody of the invention is an IgG4 Fc domain, particularly a human IgG4 Fc domain. In one embodiment, the IgG4 Fc domain comprises an amino acid substitution at position S228, specifically the amino acid substitution S228P (numbering according to Kabat EU index). To further reduce binding affinity to Fc receptors and / or effector function, in one embodiment the IgG4 Fc domain comprises an amino acid substitution at position L235, specifically the amino acid substitution L235E (numbering according to Kabat EU index). In another embodiment, the IgG4 Fc domain comprises an amino acid substitution at position P329, specifically the amino acid substitution P329G (numbering according to Kabat EU index). In a preferred embodiment, the IgG4 Fc domain comprises amino acid substitutions at positions S228, L235 and P329, specifically the amino acid substitutions S228P, L235E and P329G (numbering according to the Kabat EU index). Such IgG4 Fc domain variants and their Fcγ receptor binding properties are described in WO 2012 / 130831, which is incorporated herein by reference in its entirety.
[0343] In a preferred embodiment, the Fc domain that exhibits reduced binding affinity to Fc receptors and / or reduced effector function compared to a native IgG1 Fc domain is a human IgG1 Fc domain comprising the amino acid substitutions L234A, L235A and optionally P329G, or a human IgG4 Fc domain comprising the amino acid substitutions S228P, L235E and optionally P329G (numbering according to the Kabat EU index).
[0344] In certain embodiments, N-glycosylation of the Fc domain is eliminated. In one such embodiment, the Fc domain comprises an amino acid mutation at position N297, specifically replacing asparagine with alanine (N297A) or aspartic acid (N297D) (numbering according to the Kabat EU index).
[0345] In addition to the Fc domains described herein above and in WO 2012 / 130831, Fc domains with reduced Fc receptor binding and / or effector function also include those with substitutions of one or more of Fc domain residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Patent No. 6,737,056) (Kabat EU index numbering). Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant in which residues 265 and 297 are substituted with alanine (U.S. Patent No. 7,332,581).
[0346] Variant Fc domains can be prepared by amino acid deletion, substitution, insertion, or modification using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. Correct nucleotide changes can be confirmed, for example, by screening.
[0347] Binding to Fc receptors can be readily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard equipment such as a BIAcore instrument (GE Healthcare) and Fc receptors that can be obtained by recombinant expression. Alternatively, the binding affinity of an Fc domain or a (multispecific) antibody comprising an Fc domain for an Fc receptor may be assessed using a cell line known to express a particular Fc receptor, for example, human NK cells expressing the FcγIIIa receptor.
[0348] The effector function of an Fc domain or an Fc domain-containing (multispecific) antibody can be measured by methods known in the art. Examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362; Hellstrom et al., Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assays may be used (see, e.g., ACTI™ Non-Radioactive Cytotoxicity Assay for Flow Cytometry (CellTechnology, Inc. Mountain View, CA) and CytoTox96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).
[0349] In some embodiments, binding of the Fc domain to its complement components, particularly to C1q, is reduced. Thus, in some embodiments in which the Fc domain is engineered to have reduced effector function, the reduced effector function includes reduced CDC. C1q binding assays can be performed to determine whether an Fc domain or a (multispecific) antibody comprising an Fc domain is capable of binding C1q and therefore has CDC activity. See, e.g., the C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay may be performed (see, e.g., Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).
[0350] Determination of FcRn binding and in vivo clearance / half-life can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18(12):1759-1769 (2006); WO 2013 / 120929).
[0351] B. Polynucleotides The present invention further provides isolated polynucleotides encoding the antibodies of the present invention. Such isolated polynucleotides may be a single polynucleotide or multiple polynucleotides.
[0352] Polynucleotides encoding the (multispecific) antibodies of the present invention may be expressed as a single polynucleotide encoding the entire antibody, or as multiple (e.g., two or more) co-expressed polynucleotides. Polypeptides encoded by the co-expressed polynucleotides may associate, for example, via disulfide bonds or other means, to form a functional antibody. For example, the light chain portion of an antibody may be encoded by a separate polynucleotide derived from a portion of the antibody comprising the antibody heavy chain. When co-expressed, the heavy chain polypeptides associate with the light chain polypeptides to form the antibody. In another example, the portion of an antibody comprising one of two Fc domain subunits and, optionally, one or more Fab molecules (parts) may be encoded by a separate polynucleotide derived from a portion of the antibody comprising the other of the two Fc domain subunits and, optionally, one or more Fab molecules (parts). When co-expressed, the Fc domain subunits associate to form the Fc domain.
[0353] In some aspects, the isolated polynucleotide encodes an entire antibody molecule according to the invention as described herein, hi other aspects, the isolated polynucleotide encodes a polypeptide comprised in an antibody according to the invention as described herein.
[0354] In certain embodiments, the polynucleotide or nucleic acid is DNA. In other embodiments, the polynucleotide of the present invention is RNA, e.g., in the form of messenger RNA (mRNA). The RNA of the present invention may be single-stranded or double-stranded.
[0355] C. Recombinant Methods Antibodies of the present invention may be obtained, for example, by solid-state peptide synthesis (e.g., Merrifield solid-phase synthesis) or recombinant production. For recombinant production, one or more polynucleotides encoding the antibody, such as those described above, are isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. Such polynucleotides may be readily isolated and sequenced using conventional procedures. In one aspect, vectors, particularly expression vectors, are provided that contain the polynucleotides of the present invention (e.g., a single polynucleotide or multiple polynucleotides). Methods well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences along with appropriate transcriptional / translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo recombination / genetic recombination. See, for example, the techniques described in Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989); and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY (1989). An expression vector may be part of a plasmid, a virus, or a nucleic acid fragment. An expression vector comprises an expression cassette into which a polynucleotide encoding an antibody (i.e., a coding region) is cloned in operative association with a promoter and / or other transcriptional or translational control elements. As used herein, a "coding region" is a portion of a nucleic acid consisting of codons that are translated into amino acids. A "stop codon" (TAG, TGA, or TAA), although not translated into amino acids, may be considered part of the coding region; however, any flanking sequences, if present, such as promoters, ribosome binding sites, transcription terminators, introns, 5' and 3' untranslated regions, etc., are not part of the coding region.Two or more coding regions may be present in a single polynucleotide construct, e.g., on a single vector, or in separate polynucleotide constructs, e.g., on separate (different) vectors. Furthermore, any vector may contain a single coding region or may contain two or more coding regions; for example, the vectors of the present invention may encode one or more polypeptides, which are separated into final proteins by post- or co-translational proteolytic cleavage. Additionally, vectors, polynucleotides, or nucleic acids of the present invention may encode heterologous coding regions, either fused or unfused to the polynucleotide encoding an antibody of the present invention, or a variant or derivative thereof. Heterologous coding regions include, but are not limited to, specialized elements or motifs, such as secretory signal peptides or heterologous functional domains. Operable association refers to the association of a coding region for a gene product (e.g., a polypeptide) with one or more regulatory sequences in such a manner that expression of the gene product is under the influence or control of the regulatory sequence(s). Two DNA segments (e.g., a polypeptide coding region and its associated promoter) are "operably associated" if the introduction of promoter function results in transcription of mRNA encoding the desired gene product, and if the nature of the linkage between the two DNA segments does not interfere with the ability of expression control sequences to direct expression of the gene product or to transcribe the DNA template. Thus, a promoter region may be operably associated with a polypeptide-encoding nucleic acid if the promoter is capable of effecting transcription of the nucleic acid. The promoter may also be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. Transcription control elements other than a promoter, such as enhancers, operators, and transcription termination signals, may be operably associated with a polynucleotide to direct cell-specific transcription. Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art.These include, but are not limited to, transcriptional control regions that function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegalovirus (e.g., in combination with the immediate early promoter, intron-A), Simian Virus 40 (e.g., early promoter), and retroviruses (e.g., Rous sarcoma virus, etc.). Other transcriptional control regions include those derived from vertebrate genes, such as actin, heat shock proteins, bovine growth hormone, and rabbit β-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Further suitable transcriptional control regions include tissue-specific promoters and enhancers, and inducible promoters (e.g., tetracycline-inducible promoters). Similarly, various translational control elements are known to those skilled in the art. These include, but are not limited to, ribosome binding sites, translational start and stop codons, and elements derived from viral systems (particularly internal ribosome entry sites, or IRES, also called CITE sequences). The expression cassette may also contain other features such as, for example, an origin of replication and / or chromosomal integration elements, e.g., retroviral long terminal repeats (LTRs) or adeno-associated viral (AAV) inverted terminal repeats (ITRs).
[0356] Polynucleotide and nucleic acid coding regions of the present invention may be associated with additional coding regions encoding secretory or signal peptides to direct the secretion of a polypeptide encoded by a polynucleotide of the present invention. For example, if secretion of an antibody is desired, DNA encoding a signal sequence may be placed upstream of a nucleic acid encoding an antibody or fragment thereof of the present invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence that is cleaved from the mature protein as the growing protein chain begins to exit through the rough endoplasmic reticulum. Those skilled in the art know that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide that is cleaved from the translated polypeptide to produce a secreted or "mature" form of the polypeptide. In certain embodiments, a native signal peptide, such as an immunoglobulin heavy or light chain signal peptide, is used, or a functional derivative of that sequence that retains the ability to direct the secretion of an operably associated polypeptide is used. Alternatively, a heterologous mammalian signal peptide, or a functional derivative thereof, may be used. For example, the wild-type leader sequence may be replaced with the leader sequence of human tissue plasminogen activator (TPA) or mouse β-glucuronidase.
[0357] DNA encoding a short protein sequence (e.g., a histidine tag) that can be used to facilitate subsequent purification or to serve to label the antibody may be included within or at the end of the antibody (fragment) encoding polynucleotide.
[0358] In a further aspect, a host cell is provided that comprises a polynucleotide of the invention (i.e., a single polynucleotide or multiple polynucleotides). In certain aspects, a host cell is provided that comprises a vector of the invention. The polynucleotide and vector may incorporate any of the features described herein in connection with the polynucleotide and vector, respectively, alone or in combination. In one such aspect, the host cell comprises (e.g., is transformed or transfected with) one or more vectors that comprise one or more polynucleotides encoding (portions of) an antibody of the invention. As used herein, the term "host cell" refers to any type of cell line that can be engineered to produce an antibody of the invention or a fragment thereof. Suitable host cells for replicating and supporting the expression of antibodies are well known in the art. Such cells may be transfected or transduced, where appropriate, with a particular expression vector, and large quantities of the vector-containing cells can be grown to inoculate large-scale fermenters, thereby obtaining sufficient quantities of antibody for clinical use. Suitable host cells include prokaryotic microorganisms (e.g., Escherichia coli (E. coli)) or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, and the like. For example, polypeptides may be produced in bacteria, particularly if glycosylation is not required. After expression, the polypeptide may be isolated from the bacterial cell paste in appropriate fractions and further purified. In addition to prokaryotes, eukaryotic microorganisms, such as filamentous fungi or yeast, are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungal and yeast strains in which the glycosylation pathway has been "humanized" to produce polypeptides with partially or completely human glycosylation patterns. See Gerngross, Nat Biotech 22, 1409-1414 (2004) and Li et al., Nat Biotech 24, 210-215 (2006). Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells.Numerous baculovirus strains have been identified and can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures can also be used as hosts. See, for example, U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe the PLANTIBODIES™ technology for producing antibodies in transgenic plants). Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to growth in suspension may be useful. Other examples of useful mammalian host cell lines include the SV40 (COS-7) transformed monkey kidney CV1 line; human embryonic kidney lines (e.g., 293 or 293T cells described in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumor cells (MMT 060562); e.g., Mather et al., Annals Other useful mammalian host cell lines include TRI cells, described in NYAcad.Sci.383:44-68 (1982); MRC 5 cells; and FS4 cells. -Examples include Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)), and myeloma cell lines such as YO, NS0, P3X63, and Sp2 / 0. For a review of certain mammalian host cells suitable for protein production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, such as cultured mammalian cells, yeast cells, insect cells, bacterial cells, and plant cells, to name just a few, but also cells contained in transgenic animals, transgenic plants, or cultured plant or animal tissues. In one embodiment, the host cell is a eukaryotic cell, particularly a mammalian cell such as a Chinese hamster ovary (CHO) cell, a human embryonic kidney (HEK) cell, or a lymphocytic cell (e.g., a Y0, NS0, or Sp20 cell). In one embodiment, the host cell is not a cell in the human body.
[0359] Standard techniques for expressing foreign genes in these systems are known in the art. Cells that express a polypeptide containing the heavy or light chain of an antigen-binding domain, such as an antibody, can be engineered to also express the other antibody chain, such that the expressed product is an antibody having both a heavy and a light chain.
[0360] In one aspect, a method of producing an antibody according to the invention is provided, the method comprising culturing a host cell comprising a polynucleotide encoding an antibody provided herein under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell medium).
[0361] The components of the (multispecific) antibodies of the present invention may be genetically fused to each other. (Multispecific) antibodies can be designed such that their components are fused to each other directly or indirectly through linker sequences. The composition and length of the linker may be determined according to methods well known in the art and tested for effectiveness. Examples of linker sequences between different components of (multispecific) antibodies are provided herein. If necessary, additional sequences may be included to incorporate cleavage sites to separate the individual components of the fusion (e.g., endopeptidase recognition sequences).
[0362] Antibodies prepared as described herein may be purified by techniques known in the art, such as, for example, high-performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, etc. The actual conditions used to purify a particular protein will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, etc., and will be apparent to those of skill in the art. For affinity chromatography purification, the antibody, ligand, receptor, or antigen to which the antibody binds can be used. For example, for affinity chromatography purification of antibodies of the invention, a matrix containing Protein A or Protein G can be used. Sequential Protein A or G affinity chromatography and size exclusion chromatography can be used to isolate the antibody essentially as described in the Examples. Antibody purity can be determined by any of a variety of well-known analytical methods, including gel electrophoresis and high-pressure liquid chromatography.
[0363] D. Assay The antibodies provided herein may be identified, screened, or characterized for their physical / chemical properties and / or biological activity by various assays known in the art.
[0364] 1. Binding Assay The binding (affinity) of an antibody to an Fc receptor or target antigen can be determined, for example, by surface plasmon resonance (SPR) using standard instrumentation such as a BIAcore instrument (GE Healthcare) and receptors or target proteins available, for example, by recombinant expression. Alternatively, the binding of an antibody to different receptors or target antigens can be assessed, for example, by flow cytometry (FACS), using cell lines expressing the particular receptor or target antigen. Specific illustrative and exemplary embodiments for measuring binding activity to human or cynomolgus NKG2D are described below.
[0365] In one embodiment, binding activity to NKG2D is determined by SPR as follows: SPR was performed on a Biacore B4000 instrument (GE Healthcare). Anti-Fab capture antibodies (GE Healthcare, #28958325) were immobilized on a Series S Sensor Chip CM5 (GE Healthcare) using standard amine coupling chemistry at a surface density of approximately 1500 resonance units (RU). PBS-T (10 mM phosphate-buffered saline, pH 7.4, containing 0.05% Tween 20) was used as the running and dilution buffer. The flow cell was set to 25°C and primed twice with running buffer.
[0366] Antibodies are captured by injecting approximately 10 μg / ml of solution at a flow rate of 10 μl / min for 60 seconds. Association is measured by injecting various concentrations of di huNKG2D ECD Fc avi (SEQ ID NO: 96) or di cyNKG2D ECD Fc avi (SEQ ID NO: 97) in solution for 180 seconds at a flow rate of 30 μl / min after 1:3 dilutions, starting with 600 nM, 300 nM, and 150 nM. The dissociation phase is monitored for up to 450 seconds and triggered by switching from the sample solution to running buffer. The surface is regenerated by washing with 10 mM glycine pH 2.1 for 2 x 90 seconds at a flow rate of 30 μl / min with an additional stabilization time of 180 seconds. Bulk refractive index differences are corrected by subtracting the response obtained from the surface with capture antibody alone. A blank injection is also subtracted (double referencing). K D , k a and k d The calculation uses the Langmuir 1:1 model in Biacore 4000 Evaluation software 1.1 (GE Healthcare) or TraceDrawer 1.6.1 (Ridgeview Instruments AB).
[0367] 2. Activity Assay The biological activity of the (multispecific) antibodies of the invention can be measured by various assays, as described in the Examples. Biological activity can include, for example, induction of proliferation of NKG2D-expressing cells, induction of signal transduction in NKG2D-expressing cells, induction of expression of activation markers in NKG2D-expressing cells, induction of cytokine secretion by NKG2D-expressing cells, induction of lysis of target cells, such as tumor cells, and induction of tumor regression and / or improved survival.
[0368] E. Compositions, Formulations and Routes of Administration In a further aspect, the invention provides a pharmaceutical composition comprising any of the antibodies provided herein, e.g., for use in any of the following therapeutic methods. In one aspect, the pharmaceutical composition comprises an antibody according to the invention and a pharmaceutically acceptable carrier. In another aspect, the pharmaceutical composition comprises an antibody according to the invention and at least one additional therapeutic agent, e.g., as described below.
[0369] Additionally provided is a method of producing an antibody of the invention in a form suitable for in vivo administration, the method comprising: (a) obtaining an antibody according to the invention; and (b) combining the antibody with at least one pharmaceutically acceptable carrier, thereby formulating a formulation of the antibody for in vivo administration.
[0370] Pharmaceutical compositions of the present invention comprise an effective amount of an antibody dissolved or dispersed in a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" generally refers to molecular entities and compositions that are non-toxic to recipients at the dosages and concentrations employed, i.e., that do not produce adverse, allergic, or other untoward reactions when administered to a suitable animal, e.g., a human. The preparation of pharmaceutical compositions comprising an antibody and, optionally, additional active ingredients, is known to those skilled in the art in view of the present disclosure, as exemplified in Remington's Pharmaceutical Sciences, 18th Ed., Mack Printing Company, 1990, incorporated herein by reference. Furthermore, it will be understood that for animal (e.g., human) administration, the formulation should meet sterility, pyrogenicity, general safety, and purity standards required by the FDA Office of Biological Standards or corresponding national agencies. Preferred compositions are lyophilized formulations or aqueous solutions. As used herein, "pharmaceutically acceptable carriers" include any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonicity agents, absorption delaying agents, salts, preservatives, antioxidants, proteins, drugs, drug stabilizers, polymers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and similar materials, and combinations thereof, as known to those skilled in the art (see, e.g., Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.
[0371] The antibodies of the invention (and any additional therapeutic agents) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g., by injection, e.g., intravenous or subcutaneous, depending in part on whether administration is temporary or chronic.
[0372] Parenteral compositions include those designed to be administered by injection, for example, subcutaneous, intradermal, intralesional, intravenous, intraarterial, intramuscular, intrathecal, or intraperitoneal injection. For injection, the antibodies of the present invention can be formulated in aqueous solutions, particularly in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. The solutions may contain formulating agents, such as suspending agents, stabilizing agents, and dispersing agents. Alternatively, the antibodies may be in powder form for constitution before use with a suitable vehicle, such as sterile, pyrogen-free water. Sterile injectable solutions are prepared by incorporating the antibodies of the present invention in the required amount in an appropriate solvent, along with various other ingredients as listed below, as needed. Sterility can be readily achieved, for example, by filtration through a sterile filtration membrane. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle containing the basic dispersion medium and / or other ingredients. In the case of sterile powders for preparing sterile injectable solutions, suspensions, or emulsions, the preferred preparation method is vacuum drying or freeze-drying techniques, which yield a powder of the active ingredient and any additional desired ingredients from a previously sterile-filtered liquid medium. The liquid medium should be appropriately buffered, if necessary, and the liquid diluent should first be rendered isotonic with sufficient saline or glucose prior to injection. The composition must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be minimized to a safe level, e.g., less than 0.5 ng / mg protein.Suitable pharmaceutically acceptable carriers include, but are not limited to, buffers, such as phosphate, citrate, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins Examples of suitable suspensions include proteins such as serum albumin, gelatin, or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates (including glucose, mannose, or dextrin); chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds that increase the viscosity of the suspension (e.g., sodium carboxymethylcellulose, sorbitol, dextran, etc.). Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compound to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oil injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl cleat or triglycerides, or liposomes.
[0373] The active ingredient may be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively), colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained-release preparations may also be prepared. Suitable examples of sustained-release formulations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, for example, films or microcapsules. In certain embodiments, sustained absorption of injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate, gelatin, or combinations thereof.
[0374] In addition to the aforementioned compositions, the antibody may be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the antibody may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as a sparingly soluble derivative, for example, as a sparingly soluble salt.
[0375] Pharmaceutical compositions containing the antibodies of the present invention may be prepared by conventional mixing, dissolving, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients, or adjuvants that facilitate processing of the protein into a pharmaceutically usable preparation. Appropriate formulations will vary depending on the chosen route of administration.
[0376] The antibody may be formulated in the composition in a free acid or free base, neutral, or salt form. Pharmaceutically acceptable salts are those that substantially retain the biological activity of the free acid or free base. Pharmaceutically acceptable salts include acid addition salts, for example, those formed with free amino groups of the protein composition, or those formed with inorganic acids such as hydrochloric acid or phosphoric acid, or with organic acids such as acetic acid, oxalic acid, tartaric acid, or mandelic acid. Salts formed with free carboxyl groups may also be derived from inorganic bases such as sodium, potassium, ammonium, calcium, or ferric hydroxide, or from organic bases such as isopropylamine, trimethylamine, histidine, or procaine. Pharmaceutical salts tend to be more soluble in water and other protic solvents than the corresponding free base forms.
[0377] F. Therapeutic Methods and Compositions Any of the antibodies provided herein can be used in therapeutic methods. The antibodies of the invention can be used as immunotherapeutic agents, for example, in the treatment of cancer.
[0378] For use in therapeutic methods, the antibodies of the invention will be formulated, dosed, and administered in a manner consistent with good medical practice, with factors to consider in this regard including the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the administration schedule, and other factors known to medical practitioners.
[0379] In one aspect, the antibody of the present invention is provided for use as a pharmaceutical. In a further aspect, the antibody of the present invention is provided for use in the treatment of a disease. In certain aspects, the antibody of the present invention is provided for use in a method of treatment. In one aspect, the invention provides the antibody of the present invention for use in the treatment of a disease in an individual in need of such treatment. In certain aspects, the invention provides the antibody for use in a method of treating an individual having a disease, comprising administering to the individual an effective amount of the antibody. In certain aspects, the disease being treated is a proliferative disorder. In a preferred aspect, the disease is cancer. In certain aspects, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent (e.g., an anti-cancer agent when the disease being treated is cancer). In a further aspect, the invention provides the antibody of the present invention for use in inducing lysis of target cells, particularly tumor cells. In certain aspects, the invention provides the antibody of the present invention for use in a method of inducing lysis of target cells, particularly tumor cells, in an individual, comprising administering to the individual an effective amount of the antibody to induce lysis of the target cells. In certain embodiments, the method further comprises administering a T cell activator, such as an antibody that binds CD3, particularly a bispecific antibody that binds CD3 and a target cell antigen, particularly a tumor cell antigen. In certain embodiments, the use is in combination with a T cell activator, such as an antibody that binds CD3, particularly a bispecific antibody that binds CD3 and a target cell antigen, particularly a tumor cell antigen. The "individual" according to any of the above embodiments is a mammal, preferably a human.
[0380] In a further aspect, the invention provides use of an antibody of the invention in the manufacture or preparation of a medicament. In one aspect, the medicament is for treating a disease in an individual in need thereof. In a further aspect, the medicament is for use in a method of treating a disease, comprising administering an effective amount of the medicament to an individual having the disease. In a particular aspect, the disease being treated is a proliferative disorder. In a preferred aspect, the disease is cancer. In one aspect, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent (e.g., an anti-cancer agent if the disease being treated is cancer). In a further aspect, the medicament is for inducing lysis of target cells, particularly tumor cells. In a still further aspect, the medicament is for use in a method of inducing lysis of target cells, particularly tumor cells, in an individual, comprising administering to the individual an effective amount of the medicament to induce lysis of the target cells. In a particular aspect, the method further comprises administering a T cell activator, such as an antibody that binds CD3, particularly a bispecific antibody that binds CD3 and a target cell antigen, particularly a tumor cell antigen. In certain embodiments, the treatment is in combination with a T cell activator, such as an antibody that binds CD3, particularly a bispecific antibody that binds CD3 and a target cell antigen, particularly a tumor cell antigen. An "individual" according to any of the above embodiments may be a mammal, preferably a human.
[0381] In a further aspect, the present invention provides a method for treating a disease. In one aspect, the method comprises administering to an individual having such a disease an effective amount of an antibody of the invention. In one aspect, a composition is administered to the individual, comprising the antibody of the invention in a pharmaceutically acceptable form. In certain aspects, the disease being treated is a proliferative disorder. In a preferred aspect, the disease is cancer. In certain aspects, the method further comprises administering to the individual an effective amount of at least one additional ...
Claims
1. An antibody that binds to NKG2D, (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 73, a HCDR2 selected from the group consisting of SEQ ID NO: 74, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104 and SEQ ID NO: 105, and a HCDR3 of SEQ ID NO: 75; and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 76, a LCDR2 of SEQ ID NO: 77, and a LCDR3 of SEQ ID NO: 78; (ii) a VH comprising an HCDR1 of SEQ ID NO: 65, an HCDR2 of SEQ ID NO: 66, and an HCDR3 of SEQ ID NO: 67, and a VL comprising an LCDR1 of SEQ ID NO: 68, an LCDR2 of SEQ ID NO: 69, and an LCDR3 of SEQ ID NO: 70; (iii) a VH comprising an HCDR1 of SEQ ID NO: 1, an HCDR2 of SEQ ID NO: 2, and an HCDR3 of SEQ ID NO: 3, and a VL comprising an LCDR1 of SEQ ID NO: 4, an LCDR2 of SEQ ID NO: 5, and an LCDR3 of SEQ ID NO: 6; (iv) a VH comprising an HCDR1 of SEQ ID NO: 25, an HCDR2 of SEQ ID NO: 26, and an HCDR3 of SEQ ID NO: 27, and a VL comprising an LCDR1 of SEQ ID NO: 28, an LCDR2 of SEQ ID NO: 29, and an LCDR3 of SEQ ID NO: 30; (v) a VH comprising an HCDR1 of SEQ ID NO: 49, an HCDR2 of SEQ ID NO: 50, and an HCDR3 of SEQ ID NO: 51, and a VL comprising an LCDR1 of SEQ ID NO: 52, an LCDR2 of SEQ ID NO: 53, and an LCDR3 of SEQ ID NO: 54; (vi) a VH comprising an HCDR1 of SEQ ID NO: 57, an HCDR2 of SEQ ID NO: 58, and an HCDR3 of SEQ ID NO: 59, and a VL comprising an LCDR1 of SEQ ID NO: 60, an LCDR2 of SEQ ID NO: 61, and an LCDR3 of SEQ ID NO: 62; (vii) a VH comprising an HCDR1 of SEQ ID NO: 9, an HCDR2 of SEQ ID NO: 10, and an HCDR3 of SEQ ID NO: 11, and a VL comprising an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 13, and an LCDR3 of SEQ ID NO: 14; (viii) a VH comprising an HCDR1 of SEQ ID NO: 17, an HCDR2 of SEQ ID NO: 18, and an HCDR3 of SEQ ID NO: 19, and a VL comprising an LCDR1 of SEQ ID NO: 20, an LCDR2 of SEQ ID NO: 21, and an LCDR3 of SEQ ID NO: 22; (ix) a VH comprising an HCDR1 of SEQ ID NO: 33, an HCDR2 of SEQ ID NO: 34, and an HCDR3 of SEQ ID NO: 35, and a VL comprising an LCDR1 of SEQ ID NO: 36, an LCDR2 of SEQ ID NO: 37, and an LCDR3 of SEQ ID NO: 38; or (x) a VH comprising an HCDR1 of SEQ ID NO: 41, an HCDR2 of SEQ ID NO: 42, and an HCDR3 of SEQ ID NO: 43; and a VL comprising an LCDR1 of SEQ ID NO: 44, an LCDR2 of SEQ ID NO: 45, and an LCDR3 of SEQ ID NO: 46; 2. An antibody comprising a first antigen-binding domain comprising:
2. The first antigen-binding domain comprises: (i) a VH comprising an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:79, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112 and SEQ ID NO:113, and a VL comprising an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:80; (ii) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 71, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 72; (iii) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 7, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 8; (iv) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 31, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 32; (v) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 55, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 56; (vi) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 63, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 64; (vii) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 15, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 16; (viii) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 23, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 24; (ix) a VH comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 39, and a VL comprising an amino acid sequence at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 40; or (x) a VH comprising an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 47, and a VL comprising an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 48; The antibody of claim 1 , comprising:
3. The antibody of claim 1 or 2, wherein the antibody is an IgG antibody.
4. The antibody of claim 3, wherein the IgG antibody is an IgG1 antibody.
5. The antibody of any one of claims 1 to 4, wherein the antibody is a full-length antibody.
6. The antibody is selected from the group consisting of Fv molecules, scFv molecules, Fab molecules and F(ab') 2 The antibody of any one of claims 1 to 5, which is an antibody fragment selected from the group of molecules:
7. The antibody according to any one of claims 1 to 6, wherein the antibody is a multispecific antibody.
8. The antibody described in claim 7, wherein the multispecific antibody is a bispecific antibody.
9. The antibody of any one of claims 1 to 8, wherein the antibody comprises a second antigen-binding domain that binds to a second antigen.
10. The antibody of claim 9 , wherein the second antigen is a target cell antigen.
11. The antibody described in claim 10, wherein the target cell antigen is a tumor cell antigen.
12. The antibody according to any one of claims 1 to 11, wherein the antibody comprises an Fc domain composed of a first subunit and a second subunit.
13. The antibody of claim 12, wherein the Fc domain is an IgG Fc domain.
14. The antibody of claim 13, wherein the IgG Fc domain is an IgG1 Fc domain.
15. The antibody of any one of claims 12 to 14, wherein the Fc domain is a human Fc domain.
16. The antibody of any one of claims 12 to 15, wherein the Fc domain comprises one or more amino acid substitutions that reduce Fc receptor binding and / or effector function.
17. The antibody of any one of claims 1 to 16, wherein the antibody does not bind to FcγRIIIa (CD16a).
18. The antibody of any one of claims 1 to 17, wherein the first antigen-binding domain and / or the second antigen-binding domain is a Fab molecule.
19. The antibody of any one of claims 1 to 18, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VL and VH of the Fab light chain and the constant domains CL and CH1 of the Fab heavy chain are replaced by each other.
20. The antibody of any one of claims 9 to 19, wherein the second antigen-binding domain is a conventional Fab molecule.
21. 21. The antibody of claim 9, wherein the second antigen-binding domain is a Fab molecule, and wherein in the constant domain CL the amino acid at position 124 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), and in the constant domain CHI the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
22. The antibody according to any one of claims 9 to 18, wherein the second antigen-binding domain is a Fab molecule in which the variable domains VL and VH of the Fab light chain and the constant domains CL and CH1 of the Fab heavy chain are replaced by each other.
23. The antibody of any one of claims 1 to 18 or claim 22, wherein the first antigen-binding domain is a conventional Fab molecule.
24. 24. The antibody of claim 1, wherein the first antigen-binding domain is a Fab molecule, and wherein in the constant domain CL the amino acid at position 124 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted by lysine (K), arginine (R) or histidine (H) (Kabat numbering), and in the constant domain CHI the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).
25. The antibody of any one of claims 6 to 24, wherein the first antigen-binding domain and the second antigen-binding domain are each a Fab molecule, the antibody comprises an Fc domain composed of a first subunit and a second subunit, and (i) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain, or (ii) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.
26. The antibody of any one of claims 12 to 25, wherein the Fc domain comprises a modification that promotes association of the first and second subunits of the Fc domain.
27. 27. The antibody of claim 12, wherein amino acid residues in the CH3 domain of the first subunit of the Fc domain are replaced with amino acid residues having a larger side chain mass, thereby generating a protrusion in the CH3 domain of the first subunit that can be positioned in a cavity in the CH3 domain of the second subunit, and wherein amino acid residues in the CH3 domain of the second subunit of the Fc domain are replaced with amino acid residues having a smaller side chain mass, thereby generating a cavity in the CH3 domain of the second subunit into which the protrusion in the CH3 domain of the first subunit can be positioned.
28. An isolated polynucleotide encoding the antibody of any one of claims 1 to 27.
29. 29. A host cell comprising the isolated polynucleotide of claim 28.
30. 30. A method for producing an antibody that binds to NKG2D, comprising the steps of: (a) culturing a host cell according to claim 29 under conditions suitable for expression of said antibody; and (b) recovering said antibody.
31. A pharmaceutical composition comprising the antibody of any one of claims 1 to 27 and a pharma- ceutically acceptable carrier.
32. The antibody according to any one of claims 1 to 27 or the pharmaceutical composition according to claim 31 for use as a medicament.
33. An antibody according to any one of claims 1 to 27 or a pharmaceutical composition according to claim 31 for use in the treatment of a disease.
34. The antibody or pharmaceutical composition of claim 33, wherein the disease is cancer.
35. 35. The antibody or pharmaceutical composition of claim 33 or 34, wherein the use is in combination with a T cell activator.
36. The antibody or pharmaceutical composition described in claim 35, wherein the T cell activator is an antibody that binds to CD3.
37. The antibody or pharmaceutical composition of claim 36, wherein the antibody that binds to CD3 is a bispecific antibody that binds to CD3 and a target cell antigen.
38. The antibody or pharmaceutical composition described in claim 37, wherein the target cell antigen is a tumor cell antigen.
39. Use of an antibody according to any one of claims 1 to 27 or a pharmaceutical composition according to claim 31 in the manufacture of a medicament.
40. Use of an antibody according to any one of claims 1 to 27 or a pharmaceutical composition according to claim 31 in the manufacture of a medicament for treating a disease.
41. 41. The use according to claim 40, wherein the disease is cancer.
42. 42. The use according to claim 40 or 41, wherein the treatment is in combination with a T cell activator.
43. The use of claim 42, wherein the T cell activator is an antibody that binds to CD3.
44. The use of claim 43, wherein the antibody that binds to CD3 is a bispecific antibody that binds to CD3 and a target cell antigen.
45. The use of claim 44, wherein the target cell antigen is a tumor cell antigen.
46. A medicament for treating a disease in an individual, comprising administering to said individual an effective amount of an antibody according to any one of claims 1 to 27 or a pharmaceutical composition according to claim 31.
47. The pharmaceutical described in claim 46, wherein the disease is cancer.
48. The method of claim 46 or 47, further comprising administration of a T cell activator.
49. The pharmaceutical described in claim 48, wherein the T cell activator is an antibody that binds to CD3.
50. The pharmaceutical described in claim 49, wherein the antibody that binds to CD3 is a bispecific antibody that binds to CD3 and a target cell antigen.
51. The pharmaceutical described in claim 50, wherein the target cell antigen is a tumor cell antigen.
Citation Information
Patent Citations
Bivalent antibodies against nkg2d and tumor-associated antigens
JP2018510623A
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018148445A1
Proteins binding NKG2d, CD16, and c-type lectin-like molecule-1 (CLL-1)
WO2019055677A1
